A O
portion O
of O
Region O
II O
also O
resembles O
part O
of O
the O
human O
c B
- I
jun I
oncoprotein O
' O
s O
leucine O
zipper O
, O
which O
in O
turn O
, O
has O
been O
demonstrated O
to O
be O
the O
heterodimerization O
site O
between O
the O
jun B
and O
fos B
oncoproteins I
. O

Influence O
of O
cyclo B
- I
oxygenase I
inhibition O
and O
of O
leukotriene B
receptor I
blockade O
on O
pulmonary O
vascular O
pressure O
/ O
cardiac O
index O
relationships O
in O
hyperoxic O
and O
in O
hypoxic O
dogs O
. O

This O
strategy O
was O
used O
to O
place O
both O
the O
Tn903 B
neo I
gene I
and O
the O
Rhodosporidium B
toruloides I
phenylalanine I
ammonia I
lyase I
( O
PAL B
) O
- O
encoding O
gene O
under O
the O
transcriptional O
control O
of O
pPGK B
: O
: O
REP2 B
. O

Here O
we O
describe O
the O
cloning O
, O
tissue O
- O
specific O
expression O
pattern O
, O
and O
functional O
characterization O
of O
two O
novel O
TEF B
- I
1 I
isoforms I
, O
TEF B
- I
1beta I
and O
TEF B
- I
1gamma I
. O

Here O
we O
describe O
the O
cloning O
, O
tissue O
- O
specific O
expression O
pattern O
, O
and O
functional O
characterization O
of O
two O
novel O
TEF B
- I
1 I
isoforms I
, O
TEF B
- I
1beta I
and O
TEF B
- I
1gamma I
. O

Cotransfection O
of O
Ets B
- I
2 I
and O
p44 B
mitogen B
- I
activated I
protein I
( I
MAP I
) I
kinase I
expression O
vectors O
strongly O
potentiated O
HB B
- O
EGF B
promoter O
activation O
in O
response O
to O
deltaRaf B
- I
1 I
: O
ER B
. O

Cotransfection O
of O
Ets B
- I
2 I
and O
p44 B
mitogen B
- I
activated I
protein I
( I
MAP I
) I
kinase I
expression O
vectors O
strongly O
potentiated O
HB B
- O
EGF B
promoter O
activation O
in O
response O
to O
deltaRaf B
- I
1 I
: O
ER B
. O

E1A B
represses O
apolipoprotein B
AI I
enhancer I
activity O
in O
liver O
cells O
through O
a O
pRb B
- O
and O
CBP B
- O
independent O
pathway O
. O

Identification O
and O
characterization O
of O
two O
putative O
human B
arginine I
methyltransferases I
( O
HRMT1L1 B
and O
HRMT1L2 B
) O
. O

Immunohistochemically O
, O
anticytokeratin B
19 I
antibody I
revealed O
strong O
staining O
in O
both O
epithelial O
and O
sarcomatous O
MPM O
tissues O
. O

Factors O
involved O
in O
specific O
transcription O
by O
mammalian O
RNA B
polymerase I
II I
: O
purification O
, O
genetic O
specificity O
, O
and O
TATA O
box O
- O
promoter O
interactions O
of O
TFIID B
. O

The O
structure O
of O
these O
genes O
suggests O
a O
common O
ancestor O
for O
all O
viperid B
PLA2 I
genes I
. O

Quantitative O
analysis O
of O
plasmid O
loss O
rates O
in O
cdc28 B
- I
1N I
strains O
carrying O
plasmids O
with O
multiple O
replication O
origins O
suggests O
that O
a O
defect O
in O
initiating O
DNA O
replication O
probably O
causes O
this O
plasmid O
loss O
phenotype O
. O

A O
4 O
. O
8 O
- O
kilobase O
BamHI B
- O
HindIII B
fragment O
encoding O
the O
entire B
Neurospora I
crassa I
CuZn I
superoxide I
dismutase I
gene I
( O
herein O
designated O
sod B
- I
1 I
) O
was O
isolated O
from O
a O
genomic O
library O
using O
two O
60 O
- O
base O
deoxyoligonucleotide O
probes O
corresponding O
to O
the O
published O
N O
. O
crassa O
amino O
acid O
sequence O
. O

In O
this O
paper O
we O
report O
that O
ligand O
binding O
induced O
tyrosine O
phosphorylation O
in O
BaF3 O
cells O
engineered O
to O
express O
the O
murine B
Mpl I
receptor I
( O
BaF3 O
/ O
mMpl B
) O
. O

The O
5 O
' O
flanking O
region O
contains O
potential O
binding O
sites O
for O
TATA B
- I
binding I
protein I
, O
Sp1 B
, O
nuclear B
factor I
1 I
( O
NF1 B
) O
, O
CAAT B
- I
box I
binding I
protein I
( O
C B
/ I
EBP I
) O
, O
hepatocyte B
nuclear I
factors I
1 I
and I
5 I
( O
HNF1 B
, O
HNF5 B
) O
and O
activator B
proteins I
1 I
and I
2 I
( O
AP1 B
, O
AP2 B
) O
. O

The O
5 O
' O
flanking O
region O
contains O
potential O
binding O
sites O
for O
TATA B
- I
binding I
protein I
, O
Sp1 B
, O
nuclear B
factor I
1 I
( O
NF1 B
) O
, O
CAAT B
- I
box I
binding I
protein I
( O
C B
/ I
EBP I
) O
, O
hepatocyte B
nuclear I
factors I
1 I
and I
5 I
( O
HNF1 B
, O
HNF5 B
) O
and O
activator B
proteins I
1 I
and I
2 I
( O
AP1 B
, O
AP2 B
) O
. O

In O
contrast O
, O
transiently O
transfected O
cells O
expressing O
EBNA B
- I
3 I
revealed O
a O
sixfold O
increase O
in O
EBNA B
- I
3 I
protein I
expression O
from O
the O
genomic O
EBNA B
- I
3 I
gene I
compared O
to O
EBNA B
- I
3 I
cDNA I
. O

By O
progressive O
5 O
' O
- O
deletion O
studies O
, O
we O
have O
identified O
a O
248 O
- O
bp O
DNA O
fragment O
( O
- O
1018 O
to O
- O
771 O
, O
relative O
to O
the O
translation O
start O
site O
) O
at O
the O
5 O
' O
- O
flanking O
region O
of O
the O
human B
GnRHR I
gene I
that O
is O
responsible O
for O
the O
GnRHa O
- O
mediated O
down O
- O
regulation O
of O
human B
GnRHR I
promoter I
activity O
. O

By O
progressive O
5 O
' O
- O
deletion O
studies O
, O
we O
have O
identified O
a O
248 O
- O
bp O
DNA O
fragment O
( O
- O
1018 O
to O
- O
771 O
, O
relative O
to O
the O
translation O
start O
site O
) O
at O
the O
5 O
' O
- O
flanking O
region O
of O
the O
human B
GnRHR I
gene I
that O
is O
responsible O
for O
the O
GnRHa O
- O
mediated O
down O
- O
regulation O
of O
human B
GnRHR I
promoter I
activity O
. O

The O
amino O
acid O
sequence O
of O
matrilysin B
- I
2 I
also O
contains O
a O
threonine O
residue O
adjacent O
to O
the O
Zn O
- O
binding O
site O
that O
has O
been O
defined O
as O
a O
specific O
feature O
of O
matrilysin B
. O

Classical O
ligand O
- O
activated O
nuclear O
receptors O
( O
e O
. O
g O
. O
thyroid B
hormone I
receptor I
, O
retinoic B
acid I
receptor I
) O
, O
orphan B
nuclear I
receptors I
( O
e O
. O
g O
. O

Classical O
ligand O
- O
activated O
nuclear O
receptors O
( O
e O
. O
g O
. O
thyroid B
hormone I
receptor I
, O
retinoic B
acid I
receptor I
) O
, O
orphan B
nuclear I
receptors I
( O
e O
. O
g O
. O

Classical O
ligand O
- O
activated O
nuclear O
receptors O
( O
e O
. O
g O
. O
thyroid B
hormone I
receptor I
, O
retinoic B
acid I
receptor I
) O
, O
orphan B
nuclear I
receptors I
( O
e O
. O
g O
. O

To O
this O
end O
, O
an O
expression O
cassette O
consisting O
of O
the O
gene O
for O
a O
green B
fluorescent I
protein I
( O
GFP B
) O
flanked O
at O
its O
3 O
' O
end O
by O
EAV O
- O
specific O
transcription O
- O
regulating O
sequences O
was O
constructed O
. O

The O
gene O
encoding O
TRP B
- I
2 I
maps O
to O
mouse O
chromosome O
14 O
, O
in O
the O
region O
of O
the O
coat B
colour I
mutation I
slaty I
. O

Expression O
of O
Bcl B
- I
XL I
inhibited O
the O
association O
of O
Apaf B
- I
1 I
with O
caspase B
- I
9 I
in O
mammalian O
cells O
. O

Expression O
of O
Bcl B
- I
XL I
inhibited O
the O
association O
of O
Apaf B
- I
1 I
with O
caspase B
- I
9 I
in O
mammalian O
cells O
. O

Expression O
of O
Bcl B
- I
XL I
inhibited O
the O
association O
of O
Apaf B
- I
1 I
with O
caspase B
- I
9 I
in O
mammalian O
cells O
. O

As O
an O
oral O
, O
nontoxic O
compound O
with O
a O
mechanism O
of O
action O
distinct O
from O
that O
of O
ABL B
tyrosine I
kinase I
inhibition O
, O
FTI O
SCH66336 O
shows O
promise O
for O
the O
treatment O
of O
BCR B
/ O
ABL B
- O
induced O
leukemia O
. O

Here O
we O
have O
examined O
the O
ability O
of O
the O
cellular O
protein O
YB B
- I
1 I
to O
modulate O
transcription O
of O
the O
HIV B
- I
1 I
promoter I
in O
a O
human O
astrocytic O
cell O
line O
( O
U O
- O
87MG O
) O
, O
a O
neuronal O
cell O
line O
( O
SK O
- O
N O
- O
MC O
) O
and O
lymphoid O
cells O
( O
Jurkat O
) O
by O
transfection O
assay O
. O

Potentiation O
of O
the O
thrombolytic O
efficacy O
of O
single B
- I
chain I
urokinase I
( O
Pro B
- I
urokinase I
) O
by O
heparin O
. O

Neither O
of O
these O
proteins O
, O
individually O
or O
as O
a O
pair O
, O
can O
bind O
the O
alpha B
- I
globin I
3 I
' I
UTR I
unless O
they O
are O
complexed O
with O
the O
remaining O
non O
- O
poly O
( O
C O
) O
binding O
proteins O
of O
the O
alpha B
- I
complex I
. O

Biologically O
significant O
amounts O
of O
platelet B
activating I
factor I
were O
eluted O
from O
the O
sorbent O
during O
the O
entire O
treatment O
time O
. O

These O
results O
suggest O
that O
UBP41 B
may O
play O
an O
important O
role O
in O
the O
recycling O
of O
ubiquitin B
by O
hydrolysis O
of O
branched B
poly I
- I
ubiquitin I
chains I
generated O
by O
the O
action O
of O
26 B
S I
proteasome I
on O
poly O
- O
ubiquitinated O
protein O
substrates O
, O
as O
well O
as O
in O
the O
production O
of O
free O
ubiquitin B
from O
linear B
poly I
- I
ubiquitin I
chains I
and O
of O
certain O
ribosomal O
proteins O
from O
ubiquitin B
fusion I
proteins I
. O

These O
results O
suggest O
that O
UBP41 B
may O
play O
an O
important O
role O
in O
the O
recycling O
of O
ubiquitin B
by O
hydrolysis O
of O
branched B
poly I
- I
ubiquitin I
chains I
generated O
by O
the O
action O
of O
26 B
S I
proteasome I
on O
poly O
- O
ubiquitinated O
protein O
substrates O
, O
as O
well O
as O
in O
the O
production O
of O
free O
ubiquitin B
from O
linear B
poly I
- I
ubiquitin I
chains I
and O
of O
certain O
ribosomal O
proteins O
from O
ubiquitin B
fusion I
proteins I
. O

In O
order O
to O
examine O
the O
potential O
role O
of O
transcriptional O
silencing O
during O
productive O
HSV O
- O
1 O
infection O
, O
recombinant O
viruses O
were O
generated O
in O
which O
wild B
- I
type I
or I
mutant I
ICP34 I
. I
5 I
promoters I
controlling O
the O
expression O
of O
a O
chloramphenicol B
acetyltransferase I
reporter I
gene I
were O
inserted O
into O
the O
thymidine B
kinase I
gene I
of O
the O
viral O
genome O
. O

The O
atp B
1 I
and O
atp B
2 I
types O
of O
cDNA O
sequences O
were O
the O
most O
redundant O
among O
the O
28 O
different O
isoperoxidases B
identified O
among O
about O
200 O
peroxidase B
encoding I
ESTs I
. O

Two O
- O
dimensional O
gel O
electrophoresis O
of O
anti B
- I
p59fyn I
immunoprecipitates O
obtained O
from O
non O
- O
transformed O
resting O
human O
T O
lymphocytes O
resulted O
in O
the O
identification O
of O
an O
oligomeric O
protein O
complex O
which O
is O
constitutively O
formed O
between O
Fyn B
and O
several O
additional O
phosphoproteins O
( O
pp43 B
, O
pp72 B
, O
pp85 B
, O
the O
protein B
tyrosine I
kinase I
Pyk2 B
, O
as O
well O
as O
the O
two O
recently O
cloned O
adaptor O
proteins O
, O
SKAP55 B
and O
SLAP B
- I
130 I
) O
. O

Two O
- O
dimensional O
gel O
electrophoresis O
of O
anti B
- I
p59fyn I
immunoprecipitates O
obtained O
from O
non O
- O
transformed O
resting O
human O
T O
lymphocytes O
resulted O
in O
the O
identification O
of O
an O
oligomeric O
protein O
complex O
which O
is O
constitutively O
formed O
between O
Fyn B
and O
several O
additional O
phosphoproteins O
( O
pp43 B
, O
pp72 B
, O
pp85 B
, O
the O
protein B
tyrosine I
kinase I
Pyk2 B
, O
as O
well O
as O
the O
two O
recently O
cloned O
adaptor O
proteins O
, O
SKAP55 B
and O
SLAP B
- I
130 I
) O
. O

Two O
- O
dimensional O
gel O
electrophoresis O
of O
anti B
- I
p59fyn I
immunoprecipitates O
obtained O
from O
non O
- O
transformed O
resting O
human O
T O
lymphocytes O
resulted O
in O
the O
identification O
of O
an O
oligomeric O
protein O
complex O
which O
is O
constitutively O
formed O
between O
Fyn B
and O
several O
additional O
phosphoproteins O
( O
pp43 B
, O
pp72 B
, O
pp85 B
, O
the O
protein B
tyrosine I
kinase I
Pyk2 B
, O
as O
well O
as O
the O
two O
recently O
cloned O
adaptor O
proteins O
, O
SKAP55 B
and O
SLAP B
- I
130 I
) O
. O

Although O
the O
OC B
promoter I
is O
activated O
in O
a O
C O
terminus O
dependent O
manner O
, O
the O
MDR B
, O
LTR O
and O
BSP B
promoters I
are O
repressed O
by O
three O
distinct O
mechanisms O
, O
either O
independent O
of O
or O
involving O
the O
AML B
C I
terminus I
, O
or O
requiring O
only O
the O
conserved O
C O
- O
terminal O
pentapeptide O
VWRPY O
. O

E2F B
- I
1 I
is O
a O
transcription O
factor O
that O
regulates O
cell O
cycle O
progression O
into O
S O
- O
phase O
. O

In O
resting O
3T3 O
cells O
, O
jun B
- I
D I
is O
expressed O
at O
a O
higher O
level O
compared O
to O
c B
- I
jun I
and O
jun B
- I
B I
, O
and O
its O
transcription O
is O
stimulated O
only O
slightly O
by O
serum O
growth O
factors O
. O

In O
resting O
3T3 O
cells O
, O
jun B
- I
D I
is O
expressed O
at O
a O
higher O
level O
compared O
to O
c B
- I
jun I
and O
jun B
- I
B I
, O
and O
its O
transcription O
is O
stimulated O
only O
slightly O
by O
serum O
growth O
factors O
. O

In O
resting O
3T3 O
cells O
, O
jun B
- I
D I
is O
expressed O
at O
a O
higher O
level O
compared O
to O
c B
- I
jun I
and O
jun B
- I
B I
, O
and O
its O
transcription O
is O
stimulated O
only O
slightly O
by O
serum O
growth O
factors O
. O

AgMNPV O
and O
Orgyia O
pseudotsugata O
MNPV O
( O
OpMNPV O
) O
are O
similar O
in O
terms O
of O
promoter O
structure O
and O
polyhedrin B
primary I
sequence I
, O
and O
the O
polyhedrin B
gene I
of O
both O
viruses O
is O
transcribed O
in O
the O
anti O
- O
clockwise O
direction O
in O
relation O
to O
their O
physical O
maps O
. O

However O
, O
an O
intrinsic O
DNA O
- O
binding O
subunit O
for O
HiNF B
- I
D I
was O
not O
identified O
. O

It O
bound O
to O
vitamin B
D I
receptor I
( O
VDR B
) O
but O
not O
retinoic B
acid I
Xalpha I
receptor I
( O
RXRalpha B
) O
in O
the O
human O
T O
cell O
line O
MT2 O
cells O
. O

A O
high O
- O
resolution O
restriction O
map O
of O
over O
200 O
kb O
of O
contiguous O
DNA O
containing O
N B
- I
myc I
has O
been O
generated O
by O
subcloning O
YACs O
into O
cosmids O
. O

IgM B
and O
IgG B
anti I
A I
and O
anti B
B I
antibody I
status O
of O
100 O
antenatal O
O O
group O
mothers O
( O
who O
had O
non O
O O
group O
husbands O
) O
were O
studied O
. O

IgM B
and O
IgG B
anti I
A I
and O
anti B
B I
antibody I
status O
of O
100 O
antenatal O
O O
group O
mothers O
( O
who O
had O
non O
O O
group O
husbands O
) O
were O
studied O
. O

EMSA O
with O
crude O
nuclear O
extracts O
demonstrated O
that O
stimulation O
with O
CD40L B
results O
in O
the O
induction O
of O
NF B
- I
kappaB I
complexes I
that O
bind O
to O
each O
of O
the O
three O
NF B
- I
kappaB I
sites I
and O
are O
composed O
mainly O
of O
p50 B
and O
RelB B
, O
but O
also O
include O
c B
- I
Rel I
and O
p65 B
. O

Transfection O
experiments O
using O
preformed O
triplexes O
with O
a O
reporter O
plasmid O
containing O
the O
collagen B
promoter I
sequence I
showed O
significant O
inhibition O
of O
transcription O
when O
compared O
with O
a O
control O
phosphorothioate O
ODN O
. O

Twelve O
genomic O
fragments O
containing O
novel O
response O
elements O
are O
described O
, O
and O
the O
transcription O
unit O
associated O
with O
one O
of O
them O
, O
NN B
- I
84AG I
, O
was O
characterized O
in O
detail O
. O

The O
diagnostic O
accuracy O
of O
serum O
PE B
- I
1 I
was O
0 O
. O
80 O
, O
and O
that O
of O
amylase B
0 O
. O
97 O
. O

Alternative O
splicing O
of O
ClC B
- I
6 I
( O
a O
member O
of O
the O
CIC B
chloride I
- I
channel I
family I
) O
transcripts O
generates O
three O
truncated O
isoforms O
one O
of O
which O
, O
ClC B
- I
6c I
, O
is O
kidney O
- O
specific O
. O

Alternative O
splicing O
of O
ClC B
- I
6 I
( O
a O
member O
of O
the O
CIC B
chloride I
- I
channel I
family I
) O
transcripts O
generates O
three O
truncated O
isoforms O
one O
of O
which O
, O
ClC B
- I
6c I
, O
is O
kidney O
- O
specific O
. O

These O
observations O
lead O
to O
the O
proposal O
that O
the O
RNAP B
II I
CTD I
might O
be O
an O
in O
vivo O
target O
for O
the O
activated O
p42mapk B
and O
p44mapk B
MAP I
kinases I
. O

These O
observations O
lead O
to O
the O
proposal O
that O
the O
RNAP B
II I
CTD I
might O
be O
an O
in O
vivo O
target O
for O
the O
activated O
p42mapk B
and O
p44mapk B
MAP I
kinases I
. O

The O
equilibrium O
dissociation O
binding O
constant O
for O
the O
interaction O
of O
TnrA B
with O
the O
nrgAB B
promoter I
fragment I
was O
7 O
. O
7 O
nM O
under O
the O
conditions O
used O
here O
. O

The O
activity O
of O
the O
minimal O
promoter O
was O
found O
to O
be O
controlled O
by O
a O
combination O
of O
the O
activities O
of O
the O
transcription O
factors O
Sp1 B
, O
Sp3 B
, O
and O
NF B
- I
Y I
. O

Mapping O
results O
suggested O
that O
the O
complementation O
group O
identified O
by O
these O
mutants O
is O
allelic O
to O
the O
ag B
alpha I
1 I
mutation O
identified O
previously O
. O

Comparison O
with O
the O
sequence O
databanks O
show O
that O
Tactile B
is O
a O
member O
of O
the O
immunoglobulin B
gene I
superfamily I
, O
with O
similarity O
to O
Drosophila B
amalgam I
, O
the O
melanoma B
Ag I
MUC I
- I
18 I
, O
members O
of O
the O
carcinoembryonic B
Ag I
family I
, O
the O
poliovirus B
receptor I
, O
and O
the O
neural B
cell I
adhesion I
molecule I
. O

Comparison O
with O
the O
sequence O
databanks O
show O
that O
Tactile B
is O
a O
member O
of O
the O
immunoglobulin B
gene I
superfamily I
, O
with O
similarity O
to O
Drosophila B
amalgam I
, O
the O
melanoma B
Ag I
MUC I
- I
18 I
, O
members O
of O
the O
carcinoembryonic B
Ag I
family I
, O
the O
poliovirus B
receptor I
, O
and O
the O
neural B
cell I
adhesion I
molecule I
. O

Differential O
regulation O
of O
the O
pre B
- I
C I
and O
pregenomic O
promoters O
of O
human O
hepatitis O
B O
virus O
by O
members O
of O
the O
nuclear B
receptor I
superfamily I
. O

Differential O
regulation O
of O
the O
pre B
- I
C I
and O
pregenomic O
promoters O
of O
human O
hepatitis O
B O
virus O
by O
members O
of O
the O
nuclear B
receptor I
superfamily I
. O

This O
study O
was O
designed O
to O
compare O
the O
efficacy O
of O
efegatran O
plus O
streptokinase B
versus O
heparin O
plus O
accelerated O
tissue B
plasminogen I
activator I
( O
TPA B
) O
in O
coronary O
reperfusion O
in O
acute O
MI O
. O

We O
used O
expression O
cloning O
to O
identify O
interleukin B
- I
6 I
( O
IL B
- I
6 I
) O
as O
one O
factor O
that O
suppressed O
growth O
of O
a O
pre O
- O
B O
- O
cell O
variant O
line O
, O
1A9 O
- O
M O
. O

We O
used O
expression O
cloning O
to O
identify O
interleukin B
- I
6 I
( O
IL B
- I
6 I
) O
as O
one O
factor O
that O
suppressed O
growth O
of O
a O
pre O
- O
B O
- O
cell O
variant O
line O
, O
1A9 O
- O
M O
. O

Paracrine O
activation O
of O
the O
HIV B
- I
1 I
LTR I
promoter I
by O
the O
viral B
Tat I
protein I
is O
mechanistically O
similar O
to O
trans O
- O
activation O
within O
a O
cell O
. O

The O
primary O
structure O
and O
cotranscription O
of O
the O
petCA B
genes I
encoding O
the O
Rieske B
- I
FeS I
( O
nuclear B
encoded I
in I
plants I
) O
and O
apocytochrome B
f I
proteins I
has O
been O
described O
previously O
( O
Kallas O
, O
T O
. O
, O
Spiller O
, O
S O
. O
, O
and O
Malkin O
, O
R O
. O

The O
primary O
structure O
and O
cotranscription O
of O
the O
petCA B
genes I
encoding O
the O
Rieske B
- I
FeS I
( O
nuclear B
encoded I
in I
plants I
) O
and O
apocytochrome B
f I
proteins I
has O
been O
described O
previously O
( O
Kallas O
, O
T O
. O
, O
Spiller O
, O
S O
. O
, O
and O
Malkin O
, O
R O
. O

Vasoactive B
intestinal I
peptide I
and O
pituitary B
adenylate I
cyclase I
- I
activating I
polypeptide I
inhibit O
nuclear B
factor I
- I
kappa I
B I
- I
dependent I
gene I
activation O
at O
multiple O
levels O
in O
the O
human O
monocytic O
cell O
line O
THP O
- O
1 O
. O

Pokeweed B
antiviral I
protein I
( O
PAP B
) O
from O
Phytolacca O
americana O
is O
a O
highly O
specific O
N B
- I
glycosidase I
removing O
adenine O
residues O
( O
A4324 O
in O
28S B
rRNA I
and O
A2660 O
in O
23S B
rRNA I
) O
from O
intact O
ribosomes O
of O
both O
eukaryotes O
and O
prokaryotes O
. O

Pokeweed B
antiviral I
protein I
( O
PAP B
) O
from O
Phytolacca O
americana O
is O
a O
highly O
specific O
N B
- I
glycosidase I
removing O
adenine O
residues O
( O
A4324 O
in O
28S B
rRNA I
and O
A2660 O
in O
23S B
rRNA I
) O
from O
intact O
ribosomes O
of O
both O
eukaryotes O
and O
prokaryotes O
. O

Conventionally O
, O
four O
nominal O
allotypic O
variants O
, O
b4 O
, O
b5 O
, O
b6 O
and O
b9 O
have O
been O
shown O
to O
be O
co O
- O
dominantly O
expressed O
at O
the O
Ckappa1 B
gene I
locus I
. O

Pseudosubstrate O
( O
19 O
- O
36 O
) O
, O
derived O
from O
the O
C O
- O
terminus O
of O
Ca B
- I
dependent I
PKC I
isotypes I
, O
inhibited O
beta B
- I
PKC I
but O
not O
nPKC B
activity O
using O
either O
Histone B
IIIS I
or O
peptide O
( O
19 O
- O
31 O
) O
as O
substrate O
. O

Dd B
PK1 I
RNA I
decreases O
after O
6 O
h O
of O
starvation O
to O
re O
- O
accumulate O
once O
the O
cells O
have O
aggregated O
. O

Expression O
in O
early O
postnatal O
pituitary O
and O
in O
pre O
- O
somatotrophic O
cells O
suggests O
that O
Zn B
- I
16 I
could O
play O
a O
role O
in O
pituitary O
development O
prior O
to O
somatotroph O
differentiation O
. O

The O
novel O
hematopoietic B
growth I
factor I
FLT3 I
ligand I
( O
FL B
) O
is O
the O
cognate O
ligand O
for O
the O
FLT3 B
, O
tyrosine B
kinase I
receptor I
( O
R B
) O
, O
also O
referred O
to O
as O
FLK B
- I
2 I
and O
STK B
- I
1 I
. O

The O
novel O
hematopoietic B
growth I
factor I
FLT3 I
ligand I
( O
FL B
) O
is O
the O
cognate O
ligand O
for O
the O
FLT3 B
, O
tyrosine B
kinase I
receptor I
( O
R B
) O
, O
also O
referred O
to O
as O
FLK B
- I
2 I
and O
STK B
- I
1 I
. O

The O
novel O
hematopoietic B
growth I
factor I
FLT3 I
ligand I
( O
FL B
) O
is O
the O
cognate O
ligand O
for O
the O
FLT3 B
, O
tyrosine B
kinase I
receptor I
( O
R B
) O
, O
also O
referred O
to O
as O
FLK B
- I
2 I
and O
STK B
- I
1 I
. O

Oncogenic O
activation O
of O
the O
tyrosine B
kinase I
domain I
of O
the O
human B
trk I
proto I
- I
oncogene I
by O
fusion O
to O
a O
cell O
adhesion O
molecule O
. O

Members O
of O
the O
Ras B
subfamily I
of O
small B
GTP I
- I
binding I
proteins I
have O
been O
shown O
to O
be O
promiscuous O
towards O
a O
variety O
of O
putative O
effector O
molecules O
such O
as O
the O
protein B
kinase I
c I
- I
Raf I
and O
the O
Ral B
- I
specific I
guanine I
nucleotide I
exchange I
factor I
( O
Ral B
- I
GEF I
) O
. O

To O
identify O
these O
sites O
, O
the O
deduced O
amino O
acid O
sequence O
of O
the O
3T3 O
- O
L1 O
adipocyte B
insulin I
receptor I
of O
the O
mouse O
was O
determined O
. O

For O
example O
, O
introduction O
of O
immunogenic O
and O
purification O
tag O
sequences O
into O
the O
C O
- O
terminal O
coding O
region O
significantly O
decreased O
bop B
gene I
mRNA I
and O
protein O
accumulation O
. O

In O
the O
absence O
of O
E1A243 B
, O
YY1 B
represses O
CRE O
- O
dependent O
transcription O
of O
c B
- I
fos I
by O
physically O
interacting O
with O
ATF B
/ O
CREB B
proteins O
bound O
to O
the O
- O
67 O
CRE O
. O

The O
gene O
sequence O
also O
identified O
a O
340 O
- O
nucleotide O
RNA O
in O
total O
yeast O
RNA O
and O
in O
purified O
RNase B
MRP I
enzyme I
preparations O
. O

Basal O
components O
of O
the O
transcription O
apparatus O
( O
RNA B
polymerase I
II I
, O
TATA B
- I
binding I
protein I
) O
contain O
activation O
domains O
: O
is O
the O
repetitive O
C O
- O
terminal O
domain O
( O
CTD O
) O
of O
RNA B
polymerase I
II I
a O
" O
portable O
enhancer O
domain O
" O
? O

Basal O
components O
of O
the O
transcription O
apparatus O
( O
RNA B
polymerase I
II I
, O
TATA B
- I
binding I
protein I
) O
contain O
activation O
domains O
: O
is O
the O
repetitive O
C O
- O
terminal O
domain O
( O
CTD O
) O
of O
RNA B
polymerase I
II I
a O
" O
portable O
enhancer O
domain O
" O
? O

To O
determine O
the O
signal B
recognition I
particle I
( O
SRP B
) O
- O
SRP B
receptor I
( O
Srb B
) O
system O
in O
Bacillus O
subtilis O
( O
Bs O
) O
, O
we O
cloned O
the O
Bs B
srb I
gene I
, O
which O
encodes O
a O
homologue O
of O
the O
mammalian B
SRP I
receptor I
alpha I
- I
subunit I
[ O
Oguro O
et O
al O
. O
, O
DNA O
Res O
. O

To O
determine O
the O
signal B
recognition I
particle I
( O
SRP B
) O
- O
SRP B
receptor I
( O
Srb B
) O
system O
in O
Bacillus O
subtilis O
( O
Bs O
) O
, O
we O
cloned O
the O
Bs B
srb I
gene I
, O
which O
encodes O
a O
homologue O
of O
the O
mammalian B
SRP I
receptor I
alpha I
- I
subunit I
[ O
Oguro O
et O
al O
. O
, O
DNA O
Res O
. O

Molecular O
cloning O
and O
characterization O
of O
a O
new O
member O
of O
the O
rat B
placental I
prolactin I
( O
PRL B
) O
family O
, O
PRL B
- O
like O
protein B
H I
. O

However O
, O
it O
remains O
an O
open O
question O
whether O
vertebrate B
Hox I
genes I
expressed O
under O
the O
control O
of O
Drosophila O
regulatory O
sequences O
can O
substitute O
the O
function O
of O
Drosophila B
Hox I
genes I
. O

However O
, O
it O
remains O
an O
open O
question O
whether O
vertebrate B
Hox I
genes I
expressed O
under O
the O
control O
of O
Drosophila O
regulatory O
sequences O
can O
substitute O
the O
function O
of O
Drosophila B
Hox I
genes I
. O

Cells O
containing O
alpha O
subunits O
that O
lacked O
a O
distal O
domain O
( O
term O
- O
3 O
) O
or O
had O
the O
alternatively O
spliced O
alpha O
- O
2 O
distal O
domain O
showed O
markedly O
decreased O
ability O
to O
support O
tyrosine O
phosphorylation O
of O
Jak B
- I
2 I
and O
its O
substrates O
or O
to O
up O
- O
regulate O
CD86 B
. O

The O
used O
expression O
system O
could O
allow O
to O
produce O
mutated O
forms O
of O
SsEF B
- I
2 I
obtained O
by O
mutagenesis O
of O
the O
corresponding O
gene O
. O

BCL B
- I
2 I
, O
an O
inhibitor O
of O
apoptosis O
in O
a O
wide O
variety O
of O
cell O
types O
, O
has O
been O
reported O
to O
prevent O
oxidative O
stress O
- O
induced O
cell O
death O
. O

These O
RZR B
subtypes O
represent O
members O
of O
a O
new O
family O
of O
orphan B
nuclear I
receptors I
that O
most O
likely O
regulate O
specific O
gene O
expression O
. O

Downregulation O
of O
FUS B
expression O
in O
BCR B
/ O
ABL B
- O
expressing O
32Dcl3 O
cells O
was O
associated O
with O
suppression O
of O
growth O
factor O
- O
independent O
colony O
formation O
, O
restoration O
of O
G B
- I
CSF I
- O
induced O
granulocytic O
differentiation O
and O
reduced O
tumorigenic O
potential O
in O
vivo O
. O

NF B
- I
kappaB I
, O
which O
is O
probably O
important O
for O
basal O
activity O
of O
the O
human B
NOS I
II I
promoter I
, O
is O
unlikely O
to O
function O
as O
a O
major O
effector O
of O
CM O
in O
DLD O
- O
1 O
cells O
. O

Because O
the O
Pit B
- I
1 I
sites I
in O
the O
hGH B
- I
N I
gene I
promoter I
are O
insufficient O
for O
such O
gene O
activation O
in O
vivo O
, O
these O
data O
suggested O
a O
unique O
chromatin O
- O
mediated O
developmental O
role O
for O
Pit B
- I
1 I
in O
the O
hGH B
LCR I
. O

In O
co O
- O
transfection O
studies O
, O
an O
AP B
- I
2 I
but O
not O
an O
Egr B
- I
1 I
expression O
vector O
activated O
VPF B
/ O
VEGF B
transcription O
, O
thus O
indicating O
that O
AP B
- I
2 I
protein I
is O
functionally O
important O
in O
TGF B
alpha I
- O
induced O
VPF B
/ O
VEGF B
gene O
expression O
. O

In O
co O
- O
transfection O
studies O
, O
an O
AP B
- I
2 I
but O
not O
an O
Egr B
- I
1 I
expression O
vector O
activated O
VPF B
/ O
VEGF B
transcription O
, O
thus O
indicating O
that O
AP B
- I
2 I
protein I
is O
functionally O
important O
in O
TGF B
alpha I
- O
induced O
VPF B
/ O
VEGF B
gene O
expression O
. O

Expression O
of O
a O
dominant B
- I
negative I
ras I
gene I
also O
blocks O
TIS10 B
/ O
PGS2 B
induction O
by O
v B
- I
src I
. O

Full B
- I
length I
AT I
- I
PHH1 I
, O
and O
both O
AT B
- I
PHH1 I
and O
AT B
- I
PHH1 I
delta I
C I
- I
513 I
( O
truncated O
to O
be O
approximately O
the O
size O
of O
microbial B
photolyase I
genes I
) O
cDNAs O
, O
were O
overexpressed O
, O
respectively O
, O
in O
yeast O
and O
Escherichia O
coli O
mutants O
hypersensitive O
to O
ultraviolet O
light O
. O

Full B
- I
length I
AT I
- I
PHH1 I
, O
and O
both O
AT B
- I
PHH1 I
and O
AT B
- I
PHH1 I
delta I
C I
- I
513 I
( O
truncated O
to O
be O
approximately O
the O
size O
of O
microbial B
photolyase I
genes I
) O
cDNAs O
, O
were O
overexpressed O
, O
respectively O
, O
in O
yeast O
and O
Escherichia O
coli O
mutants O
hypersensitive O
to O
ultraviolet O
light O
. O

No O
significant O
differences O
existed O
between O
the O
two O
age O
groups O
in O
baseline O
characteristics O
, O
including O
treatment O
protocol O
, O
performance O
status O
, O
and O
serum B
lactate I
dehydrogenase I
( O
LDH B
) O
level O
. O

ACE B
- I
2 I
has O
a O
hydrophobic O
C O
terminus O
of O
H O
type O
. O

Here O
, O
we O
present O
evidence O
that O
exposure O
of O
DT40 O
lymphoma O
B O
cells O
to O
low O
energy O
electromagnetic O
field O
( O
EMF O
) O
results O
in O
a O
tyrosine B
kinase I
- O
dependent O
activation O
of O
phospholipase B
Cgamma2 I
( O
PLC B
- I
gamma2 I
) O
leading O
to O
increased O
inositol O
phospholipid O
turnover O
. O

Twenty O
eligible O
patients O
with O
cirrhosis O
were O
randomized O
into O
two O
groups O
: O
10 O
patients O
treated O
with O
6 O
million O
units O
of O
natural O
IFN B
- I
beta I
twice O
a O
week O
for O
36 O
months O
and O
10 O
patients O
without O
IFN B
therapy O
. O

The O
general O
transcription B
factor I
IIA I
( O
TFIIA B
) O
interacts O
with O
the O
TATA B
binding I
protein I
( O
TBP B
) O
and O
promoter O
DNA O
to O
mediate O
transcription O
activation O
in O
vitro O
. O

The O
general O
transcription B
factor I
IIA I
( O
TFIIA B
) O
interacts O
with O
the O
TATA B
binding I
protein I
( O
TBP B
) O
and O
promoter O
DNA O
to O
mediate O
transcription O
activation O
in O
vitro O
. O

Alternative O
splicing O
of O
fibroblast B
growth I
factor I
receptor I
2 I
( O
FGF B
- I
R2 I
) O
is O
an O
example O
of O
highly O
regulated O
alternative O
splicing O
in O
which O
exons O
IIIb O
and O
IIIc O
are O
utilized O
in O
a O
mutually O
exclusive O
manner O
in O
different O
cell O
types O
. O

Surprisingly O
, O
there O
is O
no O
sequence O
homology O
between O
this O
region O
of O
Ly B
- I
6E I
and O
the O
established O
consensus O
for O
the O
interferon B
- I
stimulated I
response I
element I
, O
which O
has O
been O
shown O
functionally O
important O
to O
all O
previously O
characterized O
alpha B
/ I
beta I
interferon I
- O
inducible O
promoters O
. O

ICAM B
- I
1 I
has O
been O
suggested O
a O
predictor O
of O
the O
onset O
of O
GO O
. O

Analysis O
of O
lacZ B
transcriptional I
fusions I
shows O
that O
the O
KdgR B
- I
binding I
sites I
negatively O
affect O
the O
expression O
of O
rsmB B
. O

Oligonucleotide O
competitors O
were O
used O
to O
evaluate O
the O
accessibility O
of O
the O
TATA O
- O
binding O
site O
in O
TIF B
- I
IB I
, O
TFIID B
, O
and O
TFIIIB B
. O

Addition O
of O
phalloidin O
- O
stabilized O
F B
- I
actin I
nuclei O
and O
phalloidin O
restored O
L266D O
actin B
' O
s O
ability O
to O
polymerize O
at O
4 O
degrees O
C O
. O

Recently O
, O
roles O
also O
have O
been O
suggested O
for O
the O
nuclear O
trans O
- O
factor O
GATA B
- I
1 I
in O
regulating O
progenitor O
cell O
proliferation O
. O

The O
Pro O
- O
258 O
- O
- O
> O
Leu O
( O
P258L O
) O
mutation O
caused O
constitutive O
receptor O
signaling O
that O
was O
equivalent O
to O
about O
45 O
% O
of O
the O
maximum O
level O
observed O
in O
wild O
- O
type O
cells O
stimulated O
with O
alpha B
- I
factor I
. O

A O
mutant B
areA I
product I
truncated O
immediately O
after O
the O
last O
residue O
of O
the O
highly O
conserved O
GATA B
( I
DNA I
- I
binding I
) I
domain I
retains O
partial O
function O
. O

We O
have O
characterized O
a O
panel O
of O
6 O
monoclonal O
antibodies O
raised O
against O
human B
platelet I
talin I
by O
Western O
blotting O
, O
immune O
precipitation O
, O
and O
immunofluorescence O
, O
and O
shown O
that O
antibodies B
TA205 I
and O
TD77 B
disrupt O
actin B
stress O
fibers O
and O
focal O
adhesions O
, O
and O
inhibit O
cell O
motility O
when O
microinjected O
into O
human O
fibroblasts O
. O

The O
recently O
developed O
gamma B
- I
interferon I
( O
IFN B
- I
gamma I
) O
assay O
system O
for O
the O
diagnosis O
of O
bovine O
tuberculosis O
in O
cattle O
has O
been O
accredited O
by O
the O
Standing O
Committee O
on O
Agriculture O
for O
use O
in O
Australia O
. O

The O
recently O
developed O
gamma B
- I
interferon I
( O
IFN B
- I
gamma I
) O
assay O
system O
for O
the O
diagnosis O
of O
bovine O
tuberculosis O
in O
cattle O
has O
been O
accredited O
by O
the O
Standing O
Committee O
on O
Agriculture O
for O
use O
in O
Australia O
. O

We O
have O
now O
identified O
, O
after O
21 O
serial O
undiluted O
passages O
of O
MHV O
, O
a O
small B
DI I
RNA I
, O
DIssF B
, O
which O
is O
efficiently O
packaged O
into O
virions O
. O

In O
these O
constructs O
, O
GUS B
expression O
was O
driven O
by O
promoter O
regions O
derived O
from O
the O
Arabidopsis B
alcohol I
dehydrogenase I
( O
Adh1 B
) O
, O
maize B
ubiquitin I
( O
Ubi1 B
) O
, O
rice B
actin I
( O
Act1 B
) O
and O
CaMV B
35S I
genes I
. O

In O
these O
constructs O
, O
GUS B
expression O
was O
driven O
by O
promoter O
regions O
derived O
from O
the O
Arabidopsis B
alcohol I
dehydrogenase I
( O
Adh1 B
) O
, O
maize B
ubiquitin I
( O
Ubi1 B
) O
, O
rice B
actin I
( O
Act1 B
) O
and O
CaMV B
35S I
genes I
. O

In O
the O
United O
States O
high O
- O
MW O
HES O
480 O
which O
is O
difficult O
to O
degrade O
is O
most O
frequently O
used O
and O
results O
in O
a O
larger O
in O
vivo O
MW O
and O
subsequent O
decrease O
in O
factor B
VIII I
/ O
von B
Willebrand I
factor I
levels O
. O

Cytokine O
- O
induced O
NF B
- I
kappa I
B I
DNA O
binding O
activity O
, O
RelA B
nuclear O
translocation O
, O
I B
kappa I
B I
alpha I
degradation O
, O
I B
kappa I
B I
serine O
32 O
phosphorylation O
, O
and O
I B
kappa I
B I
kinase I
( O
IKK B
) O
activity O
were O
blocked O
by O
curcumin O
treatment O
. O

We O
found O
that O
T3 O
( O
10 O
( O
- O
8 O
) O
M O
) O
selectively O
stimulates O
transcription O
from O
rGH B
- O
TRE O
- O
and O
TREpal O
- O
, O
but O
not O
ME O
- O
TRE O
- O
and O
F2 O
- O
TRE O
- O
, O
containing O
templates O
in O
which O
these O
TREs O
are O
linked O
in O
front O
of O
the O
rGH B
minimal I
promoter I
containing O
only O
the O
TATA B
box I
binding I
protein I
, O
but O
not O
any O
other O
proximal O
binding O
protein O
, O
sequence O
. O

Heme B
oxygenase I
1 I
is O
an O
essential O
enzyme O
in O
heme O
catabolism O
that O
cleaves O
heme O
to O
form O
biliverdin O
, O
iron O
, O
and O
carbon O
monoxide O
. O

To O
determine O
which O
sequences O
in O
the O
rat B
P450c17 I
promoter I
may O
be O
responsible O
for O
basal O
and O
cAMP O
- O
stimulated O
gene O
transcription O
, O
deletion O
constructs O
containing O
between O
- O
1 O
, O
560 O
and O
- O
53 O
base O
pairs O
of O
5 O
' O
- O
flanking O
DNA O
from O
the O
rat B
P450c17 I
gene I
were O
ligated O
to O
plasmids O
expressing O
the O
reporter O
gene O
luciferase B
and O
transfected O
into O
two O
mouse O
cell O
lines O
, O
adrenal O
Y O
- O
1 O
cells O
, O
and O
testicular O
Leydig O
MA O
- O
10 O
cells O
. O

To O
determine O
which O
sequences O
in O
the O
rat B
P450c17 I
promoter I
may O
be O
responsible O
for O
basal O
and O
cAMP O
- O
stimulated O
gene O
transcription O
, O
deletion O
constructs O
containing O
between O
- O
1 O
, O
560 O
and O
- O
53 O
base O
pairs O
of O
5 O
' O
- O
flanking O
DNA O
from O
the O
rat B
P450c17 I
gene I
were O
ligated O
to O
plasmids O
expressing O
the O
reporter O
gene O
luciferase B
and O
transfected O
into O
two O
mouse O
cell O
lines O
, O
adrenal O
Y O
- O
1 O
cells O
, O
and O
testicular O
Leydig O
MA O
- O
10 O
cells O
. O

This O
region O
contains O
a O
motif O
with O
partial O
identity O
with O
the O
binding O
site O
for O
the O
ubiquitous O
transcription O
factor O
upstream B
stimulatory I
factor I
( O
USF B
) O
, O
which O
binds O
to O
the O
human B
insulin I
promoter I
. O

This O
region O
contains O
a O
motif O
with O
partial O
identity O
with O
the O
binding O
site O
for O
the O
ubiquitous O
transcription O
factor O
upstream B
stimulatory I
factor I
( O
USF B
) O
, O
which O
binds O
to O
the O
human B
insulin I
promoter I
. O

Phorbol O
esters O
stimulated O
phosphorylation O
of O
CSK B
35H I
proteins I
, O
thus O
emphasizing O
that O
sequences O
isolated O
according O
to O
PKC B
binding O
activity O
in O
vitro O
are O
also O
PKC B
substrates O
in O
vivo O
. O

Recombinant B
prenylcysteine I
lyase I
was O
produced O
in O
a O
baculovirus O
- O
Sf9 O
expression O
system O
. O

In O
vivo O
dimethyl O
sulfate O
footprinting O
of O
the O
cyclin B
E I
promoter I
revealed O
several O
regions O
of O
protection O
and O
hypersensitivity O
that O
were O
unique O
to O
infected O
cells O
. O

Structure O
and O
regulation O
of O
the O
gene O
encoding O
the O
neuron O
- O
specific O
protein B
kinase I
C I
substrate O
neurogranin B
( O
RC3 B
protein I
) O
. O

Mutations O
of O
the O
RET B
gene I
, O
encoding O
a O
receptor B
tyrosine I
kinase I
, O
have O
been O
associated O
with O
the O
inherited O
cancer O
syndromes O
MEN O
2A O
and O
MEN O
2B O
. O

As O
regards O
lipid O
metabolism O
, O
the O
mean O
values O
for O
total O
triglycerides O
, O
cholesterol O
, O
LDL B
- I
cholesterol I
and O
HDL B
- I
cholesterol I
seen O
at O
the O
end O
of O
five O
years O
of O
Norplant O
- O
2 O
rod O
use O
and O
six O
months O
postremoval O
were O
similar O
to O
the O
preinsertion O
mean O
. O

As O
regards O
lipid O
metabolism O
, O
the O
mean O
values O
for O
total O
triglycerides O
, O
cholesterol O
, O
LDL B
- I
cholesterol I
and O
HDL B
- I
cholesterol I
seen O
at O
the O
end O
of O
five O
years O
of O
Norplant O
- O
2 O
rod O
use O
and O
six O
months O
postremoval O
were O
similar O
to O
the O
preinsertion O
mean O
. O

The O
novel O
Notch B
homologue I
mouse B
Notch I
3 I
lacks O
specific O
epidermal B
growth I
factor I
- I
repeats I
and O
is O
expressed O
in O
proliferating O
neuroepithelium O
. O

The O
fatigue O
exercise O
showed O
relatively O
high O
blood O
lactate O
concentration O
[ O
12 O
. O
5 O
( O
SD O
2 O
. O
6 O
) O
mmol O
x O
l O
( O
- O
1 O
) O
] O
and O
an O
increase O
of O
serum B
creatine I
kinase I
( O
CK B
) O
activity O
delayed O
by O
2 O
days O
[ O
540 O
( O
SD O
407 O
) O
U O
x O
l O
( O
- O
1 O
) O
] O
. O

However O
, O
L B
- I
plastin I
has O
been O
found O
in O
many O
types O
of O
malignant O
human O
cells O
of O
non O
- O
hemopoietic O
origin O
suggesting O
that O
its O
expression O
is O
induced O
accompanying O
tumorigenesis O
in O
solid O
tissues O
. O

The O
role O
of O
HIV B
tat I
, O
which O
is O
the O
main O
enhancing O
factor O
for O
viral B
LTR I
, O
in O
the O
regulation O
of O
IL B
- I
2 I
gene I
transcription O
has O
been O
studied O
following O
transient O
expression O
of O
the O
tat B
gene I
in O
phorbol O
ester O
and O
calcium O
ionophore O
- O
activated O
Jurkat O
cells O
transfected O
with O
IL B
- I
2 I
promoter O
- O
chloramphenicol B
acetyltransferase I
reporter O
constructs O
. O

Each O
recombinant O
product O
was O
a O
fusion O
protein O
with O
a O
B O
domain O
of O
Staphylococcal B
protein I
A I
( O
SPA B
) O
. O

An O
FP B
mutant I
, O
AcFP875 B
- I
2 I
, O
had O
a O
1 O
. O
6 O
- O
kbp O
insertion O
of O
S O
. O
frugiperda O
DNA O
near O
the O
5 O
' O
end O
of O
these O
transcripts O
which O
by O
S1 B
analysis O
were O
shown O
to O
initiate O
within O
the O
host O
cell O
sequence O
. O

Proteins O
known O
to O
bind O
the O
PEPCK B
CRE O
include O
the O
CRE B
- I
binding I
protein I
( O
CREB B
) O
and O
members O
of O
the O
CCAAT B
/ I
enhancer I
- I
binding I
protein I
( O
C B
/ I
EBP I
) O
family O
. O

Although O
IL B
- I
2 I
and O
IFN B
- I
alpha I
activated O
STAT1 B
alpha I
and O
STAT5 B
, O
IL B
- I
2 I
predominantly O
activated O
STAT5 B
, O
while O
IFN B
- I
alpha I
predominantly O
activated O
STAT1 B
alpha I
. O

Although O
IL B
- I
2 I
and O
IFN B
- I
alpha I
activated O
STAT1 B
alpha I
and O
STAT5 B
, O
IL B
- I
2 I
predominantly O
activated O
STAT5 B
, O
while O
IFN B
- I
alpha I
predominantly O
activated O
STAT1 B
alpha I
. O

Although O
IL B
- I
2 I
and O
IFN B
- I
alpha I
activated O
STAT1 B
alpha I
and O
STAT5 B
, O
IL B
- I
2 I
predominantly O
activated O
STAT5 B
, O
while O
IFN B
- I
alpha I
predominantly O
activated O
STAT1 B
alpha I
. O

Although O
IL B
- I
2 I
and O
IFN B
- I
alpha I
activated O
STAT1 B
alpha I
and O
STAT5 B
, O
IL B
- I
2 I
predominantly O
activated O
STAT5 B
, O
while O
IFN B
- I
alpha I
predominantly O
activated O
STAT1 B
alpha I
. O

M B
- I
66 I
identified O
the O
14 O
- O
kDa O
protein O
in O
another O
MMTV O
bearing O
T O
- O
cell O
lymphoma O
, O
EL O
- O
4 O
. O

These O
results O
suggest O
that O
G B
beta I
gamma I
- O
stimulated O
Shc B
phosphorylation O
represents O
an O
early O
step O
in O
the O
pathway O
leading O
to O
p21ras B
activation O
, O
similar O
to O
the O
mechanism O
utilized O
by O
growth B
factor I
tyrosine I
kinase I
receptors I
. O

p50 B
homodimers I
replace O
Sp1 B
from O
the O
P B
- I
selectin I
promoter I
by O
binding O
site O
competition O
and O
thereby O
either O
inhibit O
basal O
Sp1 B
- O
driven O
expression O
or O
, O
in O
concert O
with O
Bcl B
- I
3 I
, O
stimulate O
expression O
. O

A O
yeast O
DNA O
fragment O
carrying O
the O
gene B
CP I
A1 I
encoding O
the O
small O
subunit O
of O
the O
arginine O
pathway O
carbamoyl B
- I
phosphate I
synthetase I
has O
been O
sequenced O
. O

Interestingly O
, O
these O
response O
elements O
display O
dramatically O
reduced O
affinity O
for O
retinoic B
acid I
receptor I
- O
retinoid B
- I
X I
receptor I
heterodimers O
. O

The O
delta B
srb10 I
mutation I
also O
influenced O
on O
the O
transcript O
levels O
of O
meiosis O
- O
inducing O
genes O
called O
IME1 B
and O
IME2 B
: O
the O
mutation O
elevated O
the O
transcript O
level O
of O
IME1 B
but O
reduced O
that O
of O
IME2 B
, O
resulting O
in O
partial O
defects O
in O
premeiotic O
DNA O
synthesis O
and O
meiosis O
. O

The O
gene O
product O
of O
cotS B
was O
confirmed O
to O
be O
identical O
to O
Cot40 B
- I
2 I
by O
SDS O
- O
PAGE O
and O
immunoblotting O
from O
Escherichia O
coli O
transformed O
with O
a O
plasmid O
containing O
the O
cotS B
region I
. O

c B
- I
Fos I
transcriptional O
activity O
stimulated O
by O
H B
- I
Ras I
- I
activated I
protein I
kinase I
distinct O
from O
JNK B
and O
ERK B
. O

The O
predicted O
amino O
acid O
sequence O
of O
m B
- I
Staf I
is O
highly O
homologous O
to O
that O
of O
Staf B
, O
another O
selenocysteine B
tRNA I
gene I
transcription I
activating I
factor I
of O
Xenopus O
laevis O
. O

These O
results O
provide O
evidence O
of O
a O
bypass O
of O
p53 B
- O
induced O
Waf1 B
/ O
Cip1 B
- O
mediated O
cell O
cycle O
regulatory O
pathways O
by O
a O
member O
of O
the O
myb B
oncogene I
family I
. O

Extracellular B
- I
regulated I
kinase I
( O
ERK B
) O
activation O
and O
molecular O
coupling O
of O
the O
adaptor O
proteins O
p130 B
Crk B
- I
associated I
substrate I
( O
CAS B
) O
and O
c B
- I
CrkII I
( O
Crk B
) O
represent O
two O
distinct O
pathways O
that O
induce O
cell O
invasion O
and O
protect O
cells O
from O
apoptosis O
in O
a O
three O
- O
dimensional O
collagen B
matrix O
. O

Because O
L B
- I
plastin I
expression O
in O
tissue O
- O
specifically O
regulated O
in O
both O
humans O
and O
rodents O
, O
it O
is O
likely O
that O
similar O
mechanisms O
regulate O
L B
- I
plastin I
gene I
expression O
in O
human O
and O
rodent O
cells O
and O
that O
they O
could O
be O
identified O
by O
comparing O
the O
function O
and O
nucleotide O
sequences O
of O
the O
human O
and O
murine O
L B
- I
plastin I
gene O
promoters O
. O

Because O
L B
- I
plastin I
expression O
in O
tissue O
- O
specifically O
regulated O
in O
both O
humans O
and O
rodents O
, O
it O
is O
likely O
that O
similar O
mechanisms O
regulate O
L B
- I
plastin I
gene I
expression O
in O
human O
and O
rodent O
cells O
and O
that O
they O
could O
be O
identified O
by O
comparing O
the O
function O
and O
nucleotide O
sequences O
of O
the O
human O
and O
murine O
L B
- I
plastin I
gene O
promoters O
. O

This O
approach O
places O
gHoxb B
- I
1 I
into O
the O
normal O
embryonic O
spatiotemporal O
context O
in O
which O
lab O
acts O
. O

The O
effects O
of O
the O
transfected O
receptors O
were O
associated O
with O
antagonism O
of O
activator B
protein I
1 I
( O
AP B
- I
1 I
) O
activity O
. O

The O
effects O
of O
the O
transfected O
receptors O
were O
associated O
with O
antagonism O
of O
activator B
protein I
1 I
( O
AP B
- I
1 I
) O
activity O
. O

Y15170 B
( O
Surf B
- I
2 I
, O
Surf B
- I
4 I
) O
, O
Y15171 B
( O
Surf B
- I
3 I
, O
Surf B
- I
1 I
, O
Surf B
- I
6 I
) O
, O
and O
Y15172 B
( O
Surf B
- I
5 I
. O
) O
] O

Y15170 B
( O
Surf B
- I
2 I
, O
Surf B
- I
4 I
) O
, O
Y15171 B
( O
Surf B
- I
3 I
, O
Surf B
- I
1 I
, O
Surf B
- I
6 I
) O
, O
and O
Y15172 B
( O
Surf B
- I
5 I
. O
) O
] O

Y15170 B
( O
Surf B
- I
2 I
, O
Surf B
- I
4 I
) O
, O
Y15171 B
( O
Surf B
- I
3 I
, O
Surf B
- I
1 I
, O
Surf B
- I
6 I
) O
, O
and O
Y15172 B
( O
Surf B
- I
5 I
. O
) O
] O

Y15170 B
( O
Surf B
- I
2 I
, O
Surf B
- I
4 I
) O
, O
Y15171 B
( O
Surf B
- I
3 I
, O
Surf B
- I
1 I
, O
Surf B
- I
6 I
) O
, O
and O
Y15172 B
( O
Surf B
- I
5 I
. O
) O
] O

Y15170 B
( O
Surf B
- I
2 I
, O
Surf B
- I
4 I
) O
, O
Y15171 B
( O
Surf B
- I
3 I
, O
Surf B
- I
1 I
, O
Surf B
- I
6 I
) O
, O
and O
Y15172 B
( O
Surf B
- I
5 I
. O
) O
] O

Y15170 B
( O
Surf B
- I
2 I
, O
Surf B
- I
4 I
) O
, O
Y15171 B
( O
Surf B
- I
3 I
, O
Surf B
- I
1 I
, O
Surf B
- I
6 I
) O
, O
and O
Y15172 B
( O
Surf B
- I
5 I
. O
) O
] O

The O
- O
64 O
/ O
- O
37 O
region O
interacted O
with O
purified O
Sp1 B
and O
an O
unidentified O
protein O
( O
s O
) O
, O
proximal B
regulatory I
factor I
( I
s I
) I
I I
( O
PRF B
- I
I I
) O
. O

A O
series O
of O
5 O
' O
- O
deletions O
revealed O
that O
the O
fragment O
- O
218 O
to O
+ O
4 O
from O
the O
TSS O
had O
the O
highest O
promoter O
activity O
, O
nearly O
1000 O
- O
fold O
greater O
than O
the O
promoterless O
chloramphenicol B
acetyltransferase I
construct I
. O

In O
the O
point O
mutant O
we O
observed O
normal O
repair O
of O
endonuclease B
III I
site I
( O
i O
. O
e O
. O
as O
wild O
type O
) O
, O
but O
no O
removal O
of O
CPDs O
at O
the O
MAT B
alpha I
and O
HML B
alpha I
loci I
. O

In O
the O
point O
mutant O
we O
observed O
normal O
repair O
of O
endonuclease B
III I
site I
( O
i O
. O
e O
. O
as O
wild O
type O
) O
, O
but O
no O
removal O
of O
CPDs O
at O
the O
MAT B
alpha I
and O
HML B
alpha I
loci I
. O

The O
mutant O
allele O
of O
the O
alpha B
1 I
- I
tubulin I
gene I
was O
designated O
tua1 B
- I
1 I
. O

Serum O
induction O
of O
a O
MEF2 B
reporter I
gene I
was O
not O
observed O
in O
a O
line O
of O
NIH O
3T3 O
cells O
which O
contain O
low O
MEF2 B
site I
binding O
activity O
. O

Competitive O
mobility O
shift O
assays O
using O
either O
alphaT3 O
- O
1 O
nuclear O
extract O
or O
recombinant B
SF I
- I
1 I
protein I
clearly O
indicated O
that O
SF B
- I
1 I
is O
able O
to O
interact O
specifically O
with O
this O
GSE B
element I
positioned O
at O
- O
134 O
. O

These O
data O
suggest O
that O
ADAM B
- I
TS12 I
may O
play O
roles O
in O
pulmonary O
cells O
during O
fetal O
development O
or O
in O
tumor O
processes O
through O
its O
proteolytic O
activity O
or O
as O
a O
molecule O
potentially O
involved O
in O
regulation O
of O
cell O
adhesion O
. O

This O
c B
- I
Jun I
activity O
is O
inhibited O
by O
c B
- I
Fos I
, O
another O
protooncoprotein O
that O
can O
dimerize O
with O
c B
- I
Jun I
to O
form O
the O
transcription O
factor O
AP B
- I
1 I
. O

This O
c B
- I
Jun I
activity O
is O
inhibited O
by O
c B
- I
Fos I
, O
another O
protooncoprotein O
that O
can O
dimerize O
with O
c B
- I
Jun I
to O
form O
the O
transcription O
factor O
AP B
- I
1 I
. O

This O
c B
- I
Jun I
activity O
is O
inhibited O
by O
c B
- I
Fos I
, O
another O
protooncoprotein O
that O
can O
dimerize O
with O
c B
- I
Jun I
to O
form O
the O
transcription O
factor O
AP B
- I
1 I
. O

This O
c B
- I
Jun I
activity O
is O
inhibited O
by O
c B
- I
Fos I
, O
another O
protooncoprotein O
that O
can O
dimerize O
with O
c B
- I
Jun I
to O
form O
the O
transcription O
factor O
AP B
- I
1 I
. O

Null O
alleles O
of O
SAS4 B
and O
SAS5 B
bypassed O
the O
role O
of O
the O
Abf1p B
binding I
site I
of O
the O
HMR B
- I
E I
silencer I
but O
not O
the O
role O
of O
the O
ACS B
or O
Rap1p B
binding I
site I
. O

Null O
alleles O
of O
SAS4 B
and O
SAS5 B
bypassed O
the O
role O
of O
the O
Abf1p B
binding I
site I
of O
the O
HMR B
- I
E I
silencer I
but O
not O
the O
role O
of O
the O
ACS B
or O
Rap1p B
binding I
site I
. O

Surprisingly O
, O
the O
RXR B
- O
specific O
ligand O
9 O
- O
cis O
- O
retinoic O
acid O
induced O
binding O
of O
SRC B
- I
1 I
to O
the O
RXR B
component I
of O
the O
TRE O
- O
bound O
heterodimer O
. O

As O
expected O
, O
homologous B
loxP I
sequences I
efficiently O
underwent O
Cre B
- O
mediated O
recombination O
. O

DNA O
- O
protein O
UV O
cross O
- O
linking O
studies O
indicated O
that O
UHF B
- I
1 I
has O
an O
electrophoretic O
mobility O
on O
sodium O
dodecyl O
sulfate O
- O
acrylamide O
gels O
of O
approximately O
85 O
kDa O
and O
suggested O
that O
additional O
proteins O
, O
specific O
to O
each O
promoter O
, O
bind O
to O
each O
site O
. O

Precipitation O
using O
GST B
fusion I
proteins I
containing O
Fyn B
SH2 B
, O
SH3 B
, O
and O
SH2 B
/ O
SH3 B
domains O
revealed O
that O
PI B
3 I
- I
kinase I
bound O
principally O
to O
the O
SH3 B
domain I
of O
Fyn B
. O

In O
addition O
, O
we O
observe O
that O
the O
hUBF B
- I
promoter I
interaction O
is O
highly O
sensitive O
to O
the O
antagonistic O
effects O
of O
cisplatin O
- O
DNA O
adducts O
. O

Stable O
transfection O
of O
the O
BL O
cell O
line O
Raji O
with O
constructs O
containing O
core O
promoter O
mutations O
confirmed O
that O
the O
proximal O
Sp1 B
site I
and O
the O
TATA O
box O
are O
essential O
for O
the O
activation O
of O
promoter O
P1 O
by O
the O
Ig B
kappa I
enhancers I
. O

In O
contrast O
to O
the O
wild O
- O
type O
protein O
, O
expression O
of O
p45 B
NF B
- I
E2 I
lacking O
this O
activation O
domain O
in O
an O
NF B
- I
E2 I
null O
cell O
line O
fails O
to O
support O
enhancer O
- O
dependent O
transcription O
in O
transient O
assays O
. O

In O
contrast O
to O
the O
wild O
- O
type O
protein O
, O
expression O
of O
p45 B
NF B
- I
E2 I
lacking O
this O
activation O
domain O
in O
an O
NF B
- I
E2 I
null O
cell O
line O
fails O
to O
support O
enhancer O
- O
dependent O
transcription O
in O
transient O
assays O
. O

We O
found O
that O
both O
the O
E26 O
virus O
- O
encoded O
v B
- I
ets I
and O
the O
myeloid B
/ I
B I
- I
cell I
- I
specific I
factor I
PU I
. I
1 I
bind O
efficiently O
to O
this O
site O
in O
vitro O
. O

The O
seco O
- O
steroid O
hormone O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
is O
known O
to O
induce O
the O
expression O
of O
a O
calcium O
binding O
protein O
termed O
calbindin B
- I
D28K I
in O
a O
variety O
of O
target O
tissues O
. O

Sequence O
analysis O
of O
the O
sMtCK B
genomic I
upstream I
sequences I
reveals O
a O
typical O
TATAA O
box O
within O
the O
80 O
base O
pairs O
( O
bp O
) O
that O
, O
by O
transfection O
experiments O
, O
are O
sufficient O
to O
promote O
expression O
of O
chimeric O
plasmids O
with O
the O
chloramphenicol B
acetyltransferase I
reporter I
. O

Sequence O
analysis O
of O
the O
sMtCK B
genomic I
upstream I
sequences I
reveals O
a O
typical O
TATAA O
box O
within O
the O
80 O
base O
pairs O
( O
bp O
) O
that O
, O
by O
transfection O
experiments O
, O
are O
sufficient O
to O
promote O
expression O
of O
chimeric O
plasmids O
with O
the O
chloramphenicol B
acetyltransferase I
reporter I
. O

The O
Arabidopsis B
FAD7 I
gene I
encodes O
a O
chloroplast B
omega I
- I
3 I
fatty I
acid I
desaturase I
that O
catalyzes O
the O
desaturation O
of O
lipid O
- O
linked O
dienoic O
fatty O
acids O
( O
18 O
: O
2 O
and O
16 O
: O
2 O
) O
. O

Combined O
expression O
of O
c B
- I
Jun I
and O
p65 B
induced O
vigorous O
transcription O
of O
IL B
- I
2 I
promoter O
- O
and O
CD28RE B
- I
driven I
reporter I
constructs I
in O
both O
LFA B
- I
3 I
- O
and O
B7 B
- I
1 I
- O
costimulated O
Jurkat O
cells O
. O

Combined O
expression O
of O
c B
- I
Jun I
and O
p65 B
induced O
vigorous O
transcription O
of O
IL B
- I
2 I
promoter O
- O
and O
CD28RE B
- I
driven I
reporter I
constructs I
in O
both O
LFA B
- I
3 I
- O
and O
B7 B
- I
1 I
- O
costimulated O
Jurkat O
cells O
. O

Combined O
expression O
of O
c B
- I
Jun I
and O
p65 B
induced O
vigorous O
transcription O
of O
IL B
- I
2 I
promoter O
- O
and O
CD28RE B
- I
driven I
reporter I
constructs I
in O
both O
LFA B
- I
3 I
- O
and O
B7 B
- I
1 I
- O
costimulated O
Jurkat O
cells O
. O

Combined O
expression O
of O
c B
- I
Jun I
and O
p65 B
induced O
vigorous O
transcription O
of O
IL B
- I
2 I
promoter O
- O
and O
CD28RE B
- I
driven I
reporter I
constructs I
in O
both O
LFA B
- I
3 I
- O
and O
B7 B
- I
1 I
- O
costimulated O
Jurkat O
cells O
. O

The O
tyrosine B
hydroxylase I
gene I
( O
TH B
) O
contains O
a O
single O
copy O
of O
a O
consensus O
CRE O
at O
- O
45 O
to O
- O
38 O
base O
pair O
( O
bp O
) O
upstream O
of O
the O
transcription O
initiation O
site O
. O

The O
dnaQ B
- O
lacZ B
and O
the O
rnh B
- O
lacZ B
fused O
genes O
were O
constructed O
and O
hybrid O
proteins O
with O
beta B
- I
galactosidase I
activity O
were O
produced O
. O

Moreover O
, O
this O
enhancement O
of O
transcriptional O
activation O
by O
COUP B
- I
TFI I
requires O
specifically O
the O
AF O
- O
1 O
transactivation O
function O
of O
ER B
and O
can O
be O
observed O
in O
the O
presence O
of O
E2 O
or O
4 O
- O
hydroxytamoxifen O
but O
not O
ICI O
164384 O
. O

We O
have O
identified O
in O
the O
5 O
' O
untranslated O
region O
of O
the O
Drosophila B
copia I
retrotransposon I
, O
3 O
' O
to O
the O
left O
LTR O
, O
a O
sequence O
for O
transcriptional O
regulation O
by O
homeoproteins O
. O

Aryl B
hydrocarbon I
receptor I
nuclear I
translocator I
( O
ARNT B
) O
is O
a O
component O
of O
the O
transcription O
factors O
, O
aryl B
hydrocarbon I
receptor I
( O
AhR B
) O
and O
hypoxia B
- I
inducible I
factor I
1 I
, O
which O
transactivate O
their O
target O
genes O
, O
such O
as O
CYP1A1 B
and O
erythropoietin B
, O
in O
response O
to O
xenobiotic O
aromatic O
hydrocarbons O
and O
to O
low O
O2 O
concentration O
, O
respectively O
. O

Characterization O
of O
the O
microtubule O
binding O
domain O
of O
microtubule B
actin I
crosslinking I
factor I
( O
MACF B
) O
: O
identification O
of O
a O
novel O
group O
of O
microtubule B
associated I
proteins I
. O

Analysis O
of O
a O
set O
of O
deletion O
constructs O
in O
transient O
transfection O
assays O
measuring O
heterologous O
reporter O
gene O
( O
luciferase B
) O
activity O
demonstrated O
that O
the O
182 O
- O
bp O
5 O
' O
- O
flanking O
region O
provides O
full O
promoter O
activity O
in O
IL B
- I
2 I
- O
stimulated O
L2 O
cells O
. O

Systematic O
functional O
analysis O
of O
V1a B
/ I
V2 I
hybrid I
receptors I
showed O
that O
the O
second O
intracellular O
loop O
of O
the O
V1a B
receptor I
is O
required O
and O
sufficient O
for O
efficient O
coupling O
to O
Gq B
/ I
11 I
, O
whereas O
the O
third O
intracellular O
loop O
of O
the O
V2 B
receptor I
is O
required O
and O
sufficient O
for O
coupling O
to O
Gs B
. O

Reconstitution O
of O
complexes O
containing O
p62 B
and O
the O
src B
family I
kinase I
p59fyn B
in O
HeLa O
cells O
demonstrated O
that O
complex O
formation O
resulted O
in O
tyrosine O
phosphorylation O
of O
p62 B
and O
was O
mediated O
by O
both O
the O
SH3 B
and O
SH2 B
domains I
of O
p59fyn B
. O

To O
begin O
to O
understand O
this O
role O
, O
we O
overexpressed O
ATF B
- I
2 I
in O
a O
human O
cancer O
cell O
line O
. O

The O
N O
- O
terminal O
115 O
amino O
acids O
correspond O
to O
a O
putative O
DNA O
- O
binding O
domain O
and O
show O
significant O
sequence O
similarity O
with O
other O
cloned O
IFN B
response I
factors I
( O
IRF B
- I
1 I
and O
IRF B
- I
2 I
) O
. O

The O
N O
- O
terminal O
115 O
amino O
acids O
correspond O
to O
a O
putative O
DNA O
- O
binding O
domain O
and O
show O
significant O
sequence O
similarity O
with O
other O
cloned O
IFN B
response I
factors I
( O
IRF B
- I
1 I
and O
IRF B
- I
2 I
) O
. O

The O
N O
- O
terminal O
115 O
amino O
acids O
correspond O
to O
a O
putative O
DNA O
- O
binding O
domain O
and O
show O
significant O
sequence O
similarity O
with O
other O
cloned O
IFN B
response I
factors I
( O
IRF B
- I
1 I
and O
IRF B
- I
2 I
) O
. O

In O
the O
cell O
- O
free O
import O
assay O
, O
beta B
- I
catenin I
rapidly O
migrates O
into O
the O
nucleus O
without O
the O
exogenous O
addition O
of O
cytosol O
, O
Ran B
, O
or O
ATP O
/ O
GTP O
. O

Phosphorylation O
of O
myosin B
- I
binding I
subunit I
( O
MBS B
) O
of O
myosin B
phosphatase I
by O
Rho B
- I
kinase I
in O
vivo O
. O

Since O
RCC1p B
acts O
as O
GNRP B
for O
Ran B
, O
a O
small B
nuclear I
GTPase I
of O
the O
ras B
superfamily I
, O
we O
have O
identified O
two O
homologs O
of O
Ran B
in O
S O
. O
cerevisiae O
( O
CNR1 B
and O
CNR2 B
) O
. O

Although O
previous O
data O
have O
suggested O
that O
Rev B
uses O
the O
same O
export O
pathway O
as O
uracil O
- O
rich O
small O
nuclear O
RNAs O
and O
5S B
ribosomal I
RNA I
, O
the O
CTE O
seems O
to O
interact O
with O
evolutionarily O
conserved O
factors O
that O
are O
essential O
for O
cellular O
mRNA O
export O
. O

The O
E1 B
replication I
protein I
of O
bovine O
papillomavirus O
type O
1 O
contains O
an O
extended O
nuclear O
localization O
signal O
that O
includes O
a O
p34cdc2 B
phosphorylation O
site O
. O

Like O
Epo B
, O
HNF B
- I
4 I
is O
expressed O
in O
kidney O
, O
liver O
, O
and O
Hep3B O
cells O
but O
not O
in O
HeLa O
cells O
. O

The O
promoter O
of O
the O
rat B
PGS I
- I
2 I
gene I
contains O
a O
CAAT B
enhancer I
- I
binding I
protein I
consensus I
site I
( I
CAAT I
box I
) I
which O
can O
confer O
hormone O
inducibility O
to O
a O
PGS B
- I
2 I
. O
CAT B
reporter O
gene O
, O
as O
well O
as O
a O
putative O
E O
- O
box O
region O
. O

The O
promoter O
region O
( O
P1 O
) O
corresponding O
to O
the O
main O
group O
of O
transcription O
initiation O
sites O
is O
devoid O
of O
TATA O
and O
CAAT O
boxes O
but O
has O
putative O
binding O
sites O
for O
the O
transcription B
factor I
SP1 I
and O
is O
embedded O
in O
a O
large O
G O
+ O
C O
- O
rich O
domain O
of O
a O
CpG O
island O
, O
features O
shared O
by O
the O
promoters O
of O
constitutively O
expressed O
housekeeping O
genes O
. O

The O
Ets B
- I
1 I
binding I
site I
was O
localized O
to O
a O
17 O
- O
base O
pair O
( O
bp O
) O
region O
from O
the O
3 O
' O
end O
of O
T B
alpha I
2 I
. O

Therefore O
, O
PC B
- I
PLC I
is O
a O
component O
of O
a O
signal O
transduction O
pathway O
leading O
to O
transcription O
of O
c B
- I
fos I
and O
junB B
that O
collaborates O
with O
c B
- I
myc I
and O
is O
independent O
of O
PKC B
- I
delta I
and O
Ras B
activation O
. O

Therefore O
, O
PC B
- I
PLC I
is O
a O
component O
of O
a O
signal O
transduction O
pathway O
leading O
to O
transcription O
of O
c B
- I
fos I
and O
junB B
that O
collaborates O
with O
c B
- I
myc I
and O
is O
independent O
of O
PKC B
- I
delta I
and O
Ras B
activation O
. O

Therefore O
, O
PC B
- I
PLC I
is O
a O
component O
of O
a O
signal O
transduction O
pathway O
leading O
to O
transcription O
of O
c B
- I
fos I
and O
junB B
that O
collaborates O
with O
c B
- I
myc I
and O
is O
independent O
of O
PKC B
- I
delta I
and O
Ras B
activation O
. O

Therefore O
, O
PC B
- I
PLC I
is O
a O
component O
of O
a O
signal O
transduction O
pathway O
leading O
to O
transcription O
of O
c B
- I
fos I
and O
junB B
that O
collaborates O
with O
c B
- I
myc I
and O
is O
independent O
of O
PKC B
- I
delta I
and O
Ras B
activation O
. O

Mutagenesis O
of O
IM1 B
enhances O
the O
ability O
of O
c B
- I
Fos I
to O
activate O
an O
AP1 B
bearing I
promoter I
. O

Mutagenesis O
of O
IM1 B
enhances O
the O
ability O
of O
c B
- I
Fos I
to O
activate O
an O
AP1 B
bearing I
promoter I
. O

Value O
of O
the O
method O
of O
passive O
hemagglutination O
with O
polysaccharide O
C O
in O
detecting O
C B
- I
reactive I
protein I
as O
compared O
to O
precipitation O
in O
capillaries O
and O
slide O
latex O
test O
with O
anti B
- I
CRP I
serum O

This O
regulation O
requires O
two O
HMG B
- I
box I
proteins I
: O
the O
ubiquitous O
Ste11 B
transcription I
factor I
and O
the O
M O
cell O
- O
controlling O
protein O
Mat1 B
- I
Mc I
. O

This O
regulation O
requires O
two O
HMG B
- I
box I
proteins I
: O
the O
ubiquitous O
Ste11 B
transcription I
factor I
and O
the O
M O
cell O
- O
controlling O
protein O
Mat1 B
- I
Mc I
. O

Finger B
associated I
box I
- I
zinc I
finger I
proteins I
( O
FAX B
- I
ZFPs I
) O
constitute O
a O
subfamily O
of O
the O
many O
C2H2 B
type I
ZFPs I
in O
Xenopus O
laevis O
. O

Finger B
associated I
box I
- I
zinc I
finger I
proteins I
( O
FAX B
- I
ZFPs I
) O
constitute O
a O
subfamily O
of O
the O
many O
C2H2 B
type I
ZFPs I
in O
Xenopus O
laevis O
. O

In O
connective O
tissue O
, O
cell O
structure O
contributes O
to O
type B
I I
collagen I
expression O
. O

This O
transcriptional O
regulation O
occurs O
through O
modulation O
of O
the O
forkhead B
transcription I
factor I
FKHR B
- I
L1 I
, O
and O
IL B
- I
3 I
inhibited O
FKHR B
- I
L1 I
activity O
in O
a O
PI3K B
- O
dependent O
manner O
. O

This O
transcriptional O
regulation O
occurs O
through O
modulation O
of O
the O
forkhead B
transcription I
factor I
FKHR B
- I
L1 I
, O
and O
IL B
- I
3 I
inhibited O
FKHR B
- I
L1 I
activity O
in O
a O
PI3K B
- O
dependent O
manner O
. O

This O
transcriptional O
regulation O
occurs O
through O
modulation O
of O
the O
forkhead B
transcription I
factor I
FKHR B
- I
L1 I
, O
and O
IL B
- I
3 I
inhibited O
FKHR B
- I
L1 I
activity O
in O
a O
PI3K B
- O
dependent O
manner O
. O

This O
transcriptional O
regulation O
occurs O
through O
modulation O
of O
the O
forkhead B
transcription I
factor I
FKHR B
- I
L1 I
, O
and O
IL B
- I
3 I
inhibited O
FKHR B
- I
L1 I
activity O
in O
a O
PI3K B
- O
dependent O
manner O
. O

Analysis O
of O
hematopoietic B
growth I
factor I
prescriptions O
in O
19 O
french O
cancer O
centers O

The O
HiNF B
- I
D I
( O
CDP B
/ O
cut B
) O
complex O
with O
the O
H4 B
promoter I
is O
immunoreactive O
with O
antibodies O
against O
CDP B
/ O
cut B
and O
pRB B
but O
not O
p107 B
, O
whereas O
the O
CDP B
/ O
cut B
complex O
with O
a O
nonhistone O
promoter O
( O
gp91 B
- O
phox B
) O
reacts O
only O
with O
CDP B
and O
p107 B
antibodies O
. O

Binding O
activity O
in O
rat O
liver O
nuclear O
extracts O
includes O
these O
orphan O
receptors O
as O
judged O
from O
electromobility O
supershift O
experiments O
and O
from O
results O
obtained O
with O
expressed O
receptors O
, O
although O
the O
element O
in O
CYP2C11 B
did O
not O
bind O
HNF B
- I
4 I
. O

Molecular O
cloning O
and O
functional O
characterization O
of O
murine B
sphingosine I
kinase I
. O

This O
sequence O
is O
almost O
identical O
with O
that O
of O
human B
luteinizing I
hormone I
( O
Sairam O
, O
M O
. O

We O
now O
demonstrate O
that O
CCAAT B
/ I
enhancer I
- I
binding I
protein I
( I
C I
/ I
EBP I
) I
delta I
is O
a O
major O
component O
of O
a O
PGE2 O
- O
stimulated O
DNA O
- O
protein O
complex O
involving O
HS3D B
and O
find O
that O
C B
/ I
EBPdelta I
transactivates O
IGF B
- I
I I
promoter I
1 I
through O
this O
site O
. O

Transactivation O
of O
oIFNtau B
enhancer O
- O
reporter O
constructs O
was O
primarily O
regulated O
by O
three O
regions O
containing O
AP B
- I
1 I
site I
, O
GATA B
like I
sequence I
and O
site O
( O
s O
) O
unidentified O
. O

Furthermore O
, O
strains O
with O
mutant B
RPM1 I
genes I
also O
accumulate O
precursor B
Rpm1r I
, O
suggesting O
that O
mutations O
in O
either O
gene O
can O
lead O
to O
similar O
biogenesis O
defects O
. O

Platelet O
counts O
and O
function O
as O
well O
as O
fibrinogen B
and O
von B
Willebrand I
factor I
( O
vWF B
) O
levels O
were O
determined O
in O
each O
sample O
. O

In O
our O
studies O
, O
we O
utilized O
HIV O
- O
1 O
HXB2 B
and O
HIV O
- O
1 O
Z2Z6 B
core I
enhancers I
because O
the O
Z2Z6 B
strain O
has O
a O
single O
point O
mutation O
flanking O
the O
right O
ETS B
- I
binding I
site I
. O

Sequence O
analysis O
and O
identification O
of O
two O
hyp B
regulatory I
mutants I
. O

The O
mechanism O
involves O
Gbetagamma B
subunit O
- O
mediated O
increases O
in O
tyrosine O
phosphorylation O
of O
the O
Shc B
adapter I
protein I
, O
Shc B
* O
Grb2 B
complex O
formation O
, O
and O
recruitment O
of O
Ras B
guanine I
nucleotide I
exchange I
factor I
activity O
. O

Kaposi O
' O
s O
sarcoma O
- O
associated O
herpesvirus O
viral B
interferon I
regulatory I
factor I
confers O
resistance O
to O
the O
antiproliferative O
effect O
of O
interferon B
- I
alpha I
. O

The O
enhanced O
binding O
of O
c B
- I
Abl I
to O
DNA O
containing O
5 O
- O
methylcytosine O
residues O
may O
result O
from O
an O
increased O
propensity O
of O
the O
double O
helix O
to O
denature O
locally O
coupled O
with O
a O
protein O
- O
induced O
reduction O
in O
the O
base O
stacking O
interaction O
. O

Here O
we O
report O
the O
purification O
of O
this O
larger O
form O
as O
an O
approximately O
320 O
- O
kDa O
particle O
that O
contains O
mRNP3 B
+ I
4 I
and O
nine O
additional O
polypeptides O
, O
including O
mRNA O
- O
binding O
polypeptides O
of O
34 O
and O
36 O
kDa O
and O
a O
doublet O
of O
110 O
/ O
105 O
kDa O
that O
proved O
to O
be O
nucleolin B
. O

In O
co O
- O
transfection O
studies O
, O
the O
expression O
of O
c B
- I
Jun I
plus O
c B
- I
Fos I
enhanced O
the O
transactivation O
of O
oIFNtau B
- O
CAT B
but O
the O
expression O
of O
GATA B
- I
1 I
, O
GATA B
- I
2 I
or O
GATA B
- I
3 I
did O
not O
. O

In O
co O
- O
transfection O
studies O
, O
the O
expression O
of O
c B
- I
Jun I
plus O
c B
- I
Fos I
enhanced O
the O
transactivation O
of O
oIFNtau B
- O
CAT B
but O
the O
expression O
of O
GATA B
- I
1 I
, O
GATA B
- I
2 I
or O
GATA B
- I
3 I
did O
not O
. O

In O
co O
- O
transfection O
studies O
, O
the O
expression O
of O
c B
- I
Jun I
plus O
c B
- I
Fos I
enhanced O
the O
transactivation O
of O
oIFNtau B
- O
CAT B
but O
the O
expression O
of O
GATA B
- I
1 I
, O
GATA B
- I
2 I
or O
GATA B
- I
3 I
did O
not O
. O

In O
co O
- O
transfection O
studies O
, O
the O
expression O
of O
c B
- I
Jun I
plus O
c B
- I
Fos I
enhanced O
the O
transactivation O
of O
oIFNtau B
- O
CAT B
but O
the O
expression O
of O
GATA B
- I
1 I
, O
GATA B
- I
2 I
or O
GATA B
- I
3 I
did O
not O
. O

In O
co O
- O
transfection O
studies O
, O
the O
expression O
of O
c B
- I
Jun I
plus O
c B
- I
Fos I
enhanced O
the O
transactivation O
of O
oIFNtau B
- O
CAT B
but O
the O
expression O
of O
GATA B
- I
1 I
, O
GATA B
- I
2 I
or O
GATA B
- I
3 I
did O
not O
. O

The O
activity O
of O
the O
EGF B
receptor I
promoter I
can O
be O
modulated O
by O
E1A B
protein I
and O
receptor O
RNA O
levels O
increased O
by O
stimulation O
with O
phorbol O
ester O
or O
fetal O
calf O
serum O
. O

The O
LTR O
- O
binding O
activities O
of O
VBP B
, O
a1 B
/ I
EBP I
, O
and O
B B
- I
cell I
nuclear I
extract I
protein I
were O
compared O
and O
mapped O
by O
gel O
shift O
, O
DNase B
I I
footprinting O
, O
and O
methylation O
interference O
assays O
. O

These O
results O
indicate O
that O
ATF B
- I
2 I
plays O
a O
central O
role O
in O
TGF B
- I
beta I
signaling O
by O
acting O
as O
a O
common O
nuclear O
target O
of O
both O
Smad B
and O
TAK1 B
pathways O
. O

These O
results O
indicate O
that O
ATF B
- I
2 I
plays O
a O
central O
role O
in O
TGF B
- I
beta I
signaling O
by O
acting O
as O
a O
common O
nuclear O
target O
of O
both O
Smad B
and O
TAK1 B
pathways O
. O

Topological O
and O
mutational O
analysis O
of O
Saccharomyces B
cerevisiae I
Ste14p I
, O
founding O
member O
of O
the O
isoprenylcysteine B
carboxyl I
methyltransferase I
family I
. O

Consistent O
with O
previous O
reports O
, O
addition O
of O
a O
myristoylation O
signal O
to O
mSos1 B
( O
MyrSos1 B
) O
rendered O
it O
transforming O
for O
NIH O
3T3 O
cells O
and O
deletion O
of O
the O
mSos B
C I
terminus I
( O
MyrSos1 B
- I
deltaC I
) O
did O
not O
interfere O
with O
this O
activity O
. O

Consistent O
with O
previous O
reports O
, O
addition O
of O
a O
myristoylation O
signal O
to O
mSos1 B
( O
MyrSos1 B
) O
rendered O
it O
transforming O
for O
NIH O
3T3 O
cells O
and O
deletion O
of O
the O
mSos B
C I
terminus I
( O
MyrSos1 B
- I
deltaC I
) O
did O
not O
interfere O
with O
this O
activity O
. O

Taken O
together O
, O
these O
observations O
indicate O
that O
inhibition O
of O
p27 B
( O
KIP1 B
) O
transcription O
through O
PI3K B
- O
induced O
FKHR B
- I
L1 I
phosphorylation O
provides O
a O
novel O
mechanism O
of O
regulating O
cytokine O
- O
mediated O
survival O
and O
proliferation O
. O

Fowlpox O
virus O
encodes O
nonessential O
homologs O
of O
cellular B
alpha I
- I
SNAP I
, O
PC B
- I
1 I
, O
and O
an O
orphan O
human O
homolog O
of O
a O
secreted O
nematode O
protein O
. O

A O
chicken B
paxillin I
cDNA I
was O
also O
cloned O
and O
is O
predicted O
to O
encode O
a O
protein O
approximately O
90 O
% O
identical O
to O
human B
paxil I
- I
lin I
. O

A O
chimeric O
VP16 B
- O
Tat B
construct O
containing O
the O
leucine O
mutations O
showed O
no O
increased O
AP B
- I
1 I
responsiveness O
in O
comparison O
with O
that O
of O
the O
VP16 B
activation I
domain I
alone O
. O

A O
chimeric O
VP16 B
- O
Tat B
construct O
containing O
the O
leucine O
mutations O
showed O
no O
increased O
AP B
- I
1 I
responsiveness O
in O
comparison O
with O
that O
of O
the O
VP16 B
activation I
domain I
alone O
. O

Splice O
variations O
in O
genes O
coding O
for O
the O
transmembrane B
FGF I
receptor I
( O
FGFR B
) O
result O
in O
isoforms O
that O
vary O
in O
the O
ectodomain O
, O
intracellular O
juxtamembrane O
domain O
, O
and O
the O
intracellular O
kinase O
domain O
. O

A O
short O
sequence O
surrounding O
the O
major O
JNK B
phosphorylation O
site O
of O
c B
- I
Jun I
is O
conserved O
in O
c B
- I
Fos I
and O
is O
part O
of O
its O
activation O
domain O
, O
suggesting O
that O
c B
- I
Fos I
may O
be O
similarly O
regulated O
. O

A O
short O
sequence O
surrounding O
the O
major O
JNK B
phosphorylation O
site O
of O
c B
- I
Jun I
is O
conserved O
in O
c B
- I
Fos I
and O
is O
part O
of O
its O
activation O
domain O
, O
suggesting O
that O
c B
- I
Fos I
may O
be O
similarly O
regulated O
. O

A O
short O
sequence O
surrounding O
the O
major O
JNK B
phosphorylation O
site O
of O
c B
- I
Jun I
is O
conserved O
in O
c B
- I
Fos I
and O
is O
part O
of O
its O
activation O
domain O
, O
suggesting O
that O
c B
- I
Fos I
may O
be O
similarly O
regulated O
. O

Staphylococcal B
enterotoxin I
A I
involvement O
in O
the O
illness O
of O
a O
20 O
- O
month O
- O
old O
burn O
patient O
. O

In O
HCMV O
( O
Towne O
) O
- O
infected O
HF O
cells O
at O
24 O
to O
48 O
h O
, O
IE2 B
also O
accumulated O
in O
newly O
formed O
viral O
DNA O
replication O
compartments O
containing O
the O
polymerase B
processivity I
factor I
( O
UL44 B
) O
, O
the O
single B
- I
stranded I
DNA I
binding I
protein I
( O
SSB B
; O
UL57 B
) O
, O
the O
UL112 B
- I
113 I
accessory I
protein I
, O
and O
newly O
incorporated O
bromodeoxyuridine O
( O
BrdU O
) O
. O

Moreover O
, O
Lck B
was O
reversibly O
co O
- O
immunoprecipitated O
with O
p95Vav B
, O
and O
the O
stoichiometry O
of O
binding O
increased O
in O
anti B
- I
CD3 I
- O
treated O
Jurkat O
cells O
. O

A O
strong O
trithorax B
binding I
site I
was O
found O
at O
the O
cytological O
location O
of O
the O
fork B
head I
gene I
, O
a O
region O
- O
specific O
homeotic B
gene I
not O
located O
within O
a O
homeotic B
complex I
. O

A O
strong O
trithorax B
binding I
site I
was O
found O
at O
the O
cytological O
location O
of O
the O
fork B
head I
gene I
, O
a O
region O
- O
specific O
homeotic B
gene I
not O
located O
within O
a O
homeotic B
complex I
. O

One O
of O
these O
factors O
, O
HRF B
- I
1 I
, O
recognizes O
a O
cis O
element O
consisting O
of O
an O
inverted O
palindromic O
motif O
. O

Using O
PRL B
- I
R I
tagged O
both O
in O
the O
N O
- O
terminal O
or O
C O
- O
terminal O
regions O
of O
the O
mature O
receptor O
excludes O
the O
possibility O
of O
a O
cleaved O
fragment O
which O
could O
have O
been O
subsequently O
imported O
into O
the O
nucleus O
. O

Small B
Maf I
proteins I
heterodimerize O
with O
Fos B
and O
may O
act O
as O
competitive O
repressors O
of O
the O
NF B
- I
E2 I
transcription I
factor I
. O

We O
concluded O
that O
activation O
of O
c B
- I
fosER I
mediated O
transcriptional O
inhibition O
of O
p21 B
( O
Cip1 B
/ O
WAF1 B
) O
through O
a O
previously O
uncharacterized O
AP B
- I
1 I
site I
, O
revealing O
an O
important O
role O
for O
c B
- I
fos I
in O
negative O
control O
of O
cell O
cycle O
regulatory O
genes O
. O

We O
concluded O
that O
activation O
of O
c B
- I
fosER I
mediated O
transcriptional O
inhibition O
of O
p21 B
( O
Cip1 B
/ O
WAF1 B
) O
through O
a O
previously O
uncharacterized O
AP B
- I
1 I
site I
, O
revealing O
an O
important O
role O
for O
c B
- I
fos I
in O
negative O
control O
of O
cell O
cycle O
regulatory O
genes O
. O

To O
identify O
nuclear O
regulatory O
factors O
, O
we O
have O
located O
and O
functionally O
characterized O
the O
CCR5 B
gene I
promoter I
. O

During O
organogenesis O
, O
HFH B
- I
8 I
expression O
is O
found O
in O
the O
splanchnic O
mesoderm O
in O
close O
apposition O
of O
the O
gut O
endoderm O
, O
suggesting O
a O
role O
in O
mesenchymal O
- O
epithelial O
induction O
of O
lung O
and O
gut O
morphogenesis O
. O

Angiotensin B
II I
induces O
nuclear B
factor I
( I
NF I
) I
- I
kappaB1 I
isoforms I
to O
bind O
the O
angiotensinogen B
gene I
acute O
- O
phase O
response O
element O
: O
a O
stimulus O
- O
specific O
pathway O
for O
NF B
- I
kappaB I
activation O
. O

Furthermore O
, O
this O
kinase O
- O
deficient O
mutant O
inhibited O
2 O
- O
MeSADP O
- O
induced O
caspase B
- I
3 I
stimulation O
and O
the O
associated O
decrease O
in O
cell O
number O
. O

This O
TC B
- I
II I
enhanson I
, O
which O
is O
identical O
to O
the O
kappa B
B I
motif I
from O
the O
kappa B
chain I
enhancer I
, O
was O
active O
in O
both O
lymphoid O
and O
non O
- O
lymphoid O
cells O
, O
which O
contrasts O
with O
the O
previously O
reported O
lymphoid O
cell O
specificity O
of O
the O
kappa B
B I
motif I
. O

This O
TC B
- I
II I
enhanson I
, O
which O
is O
identical O
to O
the O
kappa B
B I
motif I
from O
the O
kappa B
chain I
enhancer I
, O
was O
active O
in O
both O
lymphoid O
and O
non O
- O
lymphoid O
cells O
, O
which O
contrasts O
with O
the O
previously O
reported O
lymphoid O
cell O
specificity O
of O
the O
kappa B
B I
motif I
. O

This O
TC B
- I
II I
enhanson I
, O
which O
is O
identical O
to O
the O
kappa B
B I
motif I
from O
the O
kappa B
chain I
enhancer I
, O
was O
active O
in O
both O
lymphoid O
and O
non O
- O
lymphoid O
cells O
, O
which O
contrasts O
with O
the O
previously O
reported O
lymphoid O
cell O
specificity O
of O
the O
kappa B
B I
motif I
. O

Implication O
of O
PAF B
and O
acetylhydrolase B
( O
PAF B
- I
AH I
) O
activity O
in O
periodontal O
disease O
. O

Botulinum B
toxin I
A I
in O
the O
treatment O
of O
hemiplegic O
spastic O
foot O
drop O
- O
- O
clinical O
and O
functional O
outcomes O
. O

We O
describe O
a O
novel O
cytoplasmic B
tyrosine I
kinase I
, O
termed O
BPK B
( O
B B
cell I
progenitor I
kinase I
) O
, O
which O
is O
expressed O
in O
all O
stages O
of O
the O
B O
lineage O
and O
in O
myeloid O
cells O
. O

Interestingly O
, O
the O
interaction O
of O
ZAP B
- I
70 I
with O
the O
motif O
was O
dependent O
on O
the O
presence O
of O
both O
ZAP B
- I
70 I
SH2 B
domains I
and O
both O
of O
the O
tyrosine O
residues O
in O
the O
motif O
, O
suggesting O
that O
ZAP B
- I
70 I
interacts O
with O
two O
phosphotyrosine O
residues O
and O
that O
the O
binding O
of O
the O
two O
SH2 B
domains I
is O
cooperative O
. O

Interestingly O
, O
the O
interaction O
of O
ZAP B
- I
70 I
with O
the O
motif O
was O
dependent O
on O
the O
presence O
of O
both O
ZAP B
- I
70 I
SH2 B
domains I
and O
both O
of O
the O
tyrosine O
residues O
in O
the O
motif O
, O
suggesting O
that O
ZAP B
- I
70 I
interacts O
with O
two O
phosphotyrosine O
residues O
and O
that O
the O
binding O
of O
the O
two O
SH2 B
domains I
is O
cooperative O
. O

Interestingly O
, O
the O
interaction O
of O
ZAP B
- I
70 I
with O
the O
motif O
was O
dependent O
on O
the O
presence O
of O
both O
ZAP B
- I
70 I
SH2 B
domains I
and O
both O
of O
the O
tyrosine O
residues O
in O
the O
motif O
, O
suggesting O
that O
ZAP B
- I
70 I
interacts O
with O
two O
phosphotyrosine O
residues O
and O
that O
the O
binding O
of O
the O
two O
SH2 B
domains I
is O
cooperative O
. O

Pokeweed B
mitogen I
( O
PWM B
) O
or O
anti B
- I
CD3 I
significantly O
increases O
c B
- I
jun I
messenger I
RNA I
( I
mRNA I
) I
levels O
in O
T O
cells O
. O

The O
level O
of O
serum B
creatine I
kinase I
was O
significantly O
high O
2 O
days O
after O
ESWIB O
, O
but O
it O
recovered O
in O
a O
week O
. O

The O
other O
two O
clones O
, O
Ash B
- I
m I
and I
- I
s I
, O
had O
nucleotide O
sequences O
identical O
with O
Ash B
- I
l I
cDNA O
in O
the O
amino O
- O
terminal O
region O
. O

Our O
results O
suggest O
that O
WASP B
activates O
transcription O
following O
TCR B
stimulation O
in O
a O
manner O
that O
is O
independent O
of O
its O
role O
in O
Arp2 B
/ I
3 I
- O
directed O
actin B
polymerization O
. O

Furthermore O
, O
stable O
expression O
of O
a O
constitutively O
active O
form O
of O
chicken O
Notch1 B
or O
Notch2 B
in O
a O
B O
cell O
line O
results O
in O
a O
down O
- O
regulation O
of O
surface O
IgM B
expression O
, O
which O
is O
accompanied O
by O
the O
reduction O
of O
IgH B
gene I
transcripts I
. O

Interleukin B
- I
1 I
levels O
remained O
low O
throughout O
the O
course O
. O

Intracellular O
localization O
studies O
using O
the O
mDAP B
- I
3 I
/ O
EGFP B
fusion O
protein O
, O
cell O
fractionation O
and O
protease O
protection O
experiments O
localized O
mDAP B
- I
3 I
to O
the O
mitochondrial O
matrix O
. O

Intracellular O
localization O
studies O
using O
the O
mDAP B
- I
3 I
/ O
EGFP B
fusion O
protein O
, O
cell O
fractionation O
and O
protease O
protection O
experiments O
localized O
mDAP B
- I
3 I
to O
the O
mitochondrial O
matrix O
. O

Recombinant B
HRMT1L2 I
protein I
encoded O
by O
the O
most O
common O
5 O
' O
- O
variant O
exhibited O
methyltransferase O
activity O
in O
vitro O
. O

We O
have O
attempted O
to O
clone O
two O
recessive O
extragenic O
suppressors O
of O
such O
ts O
mutants O
( O
sdp1 B
for O
mutation B
pol3 I
- I
14 I
and O
sdp5 B
- I
1 I
for O
mutation B
pol3 I
- I
11 I
) O
by O
transforming O
thermoresistant O
haploid O
strains O
pol3 B
- I
14 I
sdp1 I
and O
pol3 B
- I
11 I
sdp5 I
- I
1 I
with O
wild O
- O
type O
genomic O
libraries O
in O
singlecopy O
or O
multicopy O
vectors O
. O

RNA B
polymerase I
IIA I
was O
recovered O
in O
transcriptionally O
active O
complexes O
in O
reactions O
in O
which O
the O
input O
enzyme O
was O
RNA B
polymerase I
IIA I
. O

RNA B
polymerase I
IIA I
was O
recovered O
in O
transcriptionally O
active O
complexes O
in O
reactions O
in O
which O
the O
input O
enzyme O
was O
RNA B
polymerase I
IIA I
. O

These O
data O
are O
consistent O
with O
a O
model O
in O
which O
GATA B
- I
5 I
performs O
a O
unique O
temporally O
and O
spatially O
restricted O
function O
in O
the O
embryonic O
heart O
and O
lung O
. O

Consistent O
with O
ErbB B
- I
2 I
being O
a O
shared O
receptor O
subunit O
, O
its O
tyrosine O
phosphorylation O
was O
increased O
by O
both O
heterologous O
ligands O
and O
it O
mediated O
a O
trans O
- O
inhibitory O
effect O
of O
NDF B
on O
EGF B
binding O
. O

The O
gene O
encoding O
the O
receptor O
for O
macrophage B
colony I
- I
stimulating I
factor I
1 I
( O
CSF B
- I
1 I
) O
, O
the O
c B
- I
fms I
protooncogene I
, O
is O
selectively O
expressed O
in O
immature O
and O
mature O
mononuclear O
phagocytes O
and O
trophoblasts O
. O

Electrophoretic O
mobility O
- O
shift O
assays O
performed O
with O
the O
HNF B
- I
3 I
X O
and O
Y O
sites O
demonstrated O
that O
both O
sites O
are O
capable O
of O
binding O
HNF B
- I
3alpha I
and O
HNF B
- I
3beta I
. O

Electrophoretic O
mobility O
- O
shift O
assays O
performed O
with O
the O
HNF B
- I
3 I
X O
and O
Y O
sites O
demonstrated O
that O
both O
sites O
are O
capable O
of O
binding O
HNF B
- I
3alpha I
and O
HNF B
- I
3beta I
. O

Electrophoretic O
mobility O
- O
shift O
assays O
performed O
with O
the O
HNF B
- I
3 I
X O
and O
Y O
sites O
demonstrated O
that O
both O
sites O
are O
capable O
of O
binding O
HNF B
- I
3alpha I
and O
HNF B
- I
3beta I
. O

The O
Rlm1 B
protein I
, O
a O
member O
of O
the O
MADS B
box I
family I
of O
transcription O
factors O
, O
functions O
downstream O
of O
Mpk1 B
in O
the O
pathway O
. O

The O
observed O
phenotypes O
may O
be O
explained O
by O
( O
i O
) O
a O
selective O
disruption O
of O
very B
- I
low I
- I
density I
lipoprotein I
secretion O
due O
to O
decreased O
expression O
of O
genes O
encoding O
apolipoprotein B
B I
and O
microsomal B
triglyceride I
transfer I
protein I
, O
( O
ii O
) O
an O
increase O
in O
hepatic O
cholesterol O
uptake O
due O
to O
increased O
expression O
of O
the O
major O
high B
- I
density I
lipoprotein I
receptor I
, O
scavenger B
receptor I
BI I
, O
and O
( O
iii O
) O
a O
decrease O
in O
bile O
acid O
uptake O
to O
the O
liver O
due O
to O
down O
- O
regulation O
of O
the O
major O
basolateral B
bile I
acid I
transporters I
sodium I

TNF B
Treatment O
of O
cell O
activated O
the O
p38 B
MAP I
kinase I
pathway O
, O
as O
revealed O
by O
increased O
phosphorylation O
of O
p38 B
MAP I
kinase I
itself O
, O
activation O
of O
the O
substrate O
protein O
MAPKAP B
kinase I
- I
2 I
, O
and O
culminating O
in O
the O
phosphorylation O
of O
the O
heat B
shock I
protein I
27 I
( O
hsp27 B
) O
. O

TNF B
Treatment O
of O
cell O
activated O
the O
p38 B
MAP I
kinase I
pathway O
, O
as O
revealed O
by O
increased O
phosphorylation O
of O
p38 B
MAP I
kinase I
itself O
, O
activation O
of O
the O
substrate O
protein O
MAPKAP B
kinase I
- I
2 I
, O
and O
culminating O
in O
the O
phosphorylation O
of O
the O
heat B
shock I
protein I
27 I
( O
hsp27 B
) O
. O

The O
deduced O
amino O
acid O
sequence O
of O
the O
gene O
has O
significant O
homology O
to O
the O
interferon B
regulatory I
factors I
( O
IRFs B
) O
. O

The O
expression O
of O
alpha B
- I
amylase I
can O
be O
transactivated O
by O
the O
transcription O
factor O
GAMyb B
, O
which O
is O
itself O
induced O
by O
GA O
. O

Furthermore O
, O
transfection O
of O
cells O
with O
the O
spacer O
- O
RING O
domain O
alone O
suppressed O
the O
antiapoptotic O
function O
of O
the O
N O
- O
terminal O
BIR B
domain O
of O
c B
- I
IAP1 I
and O
induced O
apoptosis O
. O

Mutually O
exclusive O
interaction O
of O
the O
adenovirus B
E4 I
- I
6 I
/ I
7 I
protein I
and O
the O
retinoblastoma B
gene I
product I
with O
internal O
domains O
of O
E2F B
- I
1 I
and O
DP B
- I
1 I
. O

Mutually O
exclusive O
interaction O
of O
the O
adenovirus B
E4 I
- I
6 I
/ I
7 I
protein I
and O
the O
retinoblastoma B
gene I
product I
with O
internal O
domains O
of O
E2F B
- I
1 I
and O
DP B
- I
1 I
. O

Mutually O
exclusive O
interaction O
of O
the O
adenovirus B
E4 I
- I
6 I
/ I
7 I
protein I
and O
the O
retinoblastoma B
gene I
product I
with O
internal O
domains O
of O
E2F B
- I
1 I
and O
DP B
- I
1 I
. O

Sequence O
analysis O
revealed O
significant O
differences O
between O
the O
5 O
' O
region O
of O
the O
beta O
subunit O
gene O
and O
the O
corresponding O
regions O
of O
the O
homologous B
GlyR I
alpha I
subunit I
genes I
; O
it O
also O
identified O
a O
novel O
exon O
( O
exon O
0 O
) O
that O
encodes O
most O
of O
the O
5 O
' O
- O
untranslated O
portion O
of O
the O
GlyR B
beta I
mRNA I
. O

The O
different O
holoenzyme B
RNA I
polymerases I
generated O
upon O
reconstituting O
these O
mutants O
independently O
with O
core B
RNA I
polymerase I
( O
alpha2beta B
beta I
' I
) O
have O
shown O
reduced O
transcriptional O
activity O
in O
comparison O
to O
the O
enzyme O
containing O
wild B
- I
type I
sigma I
factor I
. O

The O
different O
holoenzyme B
RNA I
polymerases I
generated O
upon O
reconstituting O
these O
mutants O
independently O
with O
core B
RNA I
polymerase I
( O
alpha2beta B
beta I
' I
) O
have O
shown O
reduced O
transcriptional O
activity O
in O
comparison O
to O
the O
enzyme O
containing O
wild B
- I
type I
sigma I
factor I
. O

The O
different O
holoenzyme B
RNA I
polymerases I
generated O
upon O
reconstituting O
these O
mutants O
independently O
with O
core B
RNA I
polymerase I
( O
alpha2beta B
beta I
' I
) O
have O
shown O
reduced O
transcriptional O
activity O
in O
comparison O
to O
the O
enzyme O
containing O
wild B
- I
type I
sigma I
factor I
. O

Since O
AP B
- I
1 I
is O
an O
important O
mediator O
of O
tumor O
promoter O
action O
, O
these O
findings O
may O
explain O
the O
anti O
- O
tumor O
- O
promoting O
activity O
of O
phenolic O
antioxidants O
. O

Mutations O
within O
conserved O
region O
2 O
( O
CR2 O
) O
of O
E1A B
that O
inhibit O
the O
binding O
of O
E1A B
to O
the O
retinoblastoma B
gene I
product I
( O
pRb B
) O
further O
enhanced O
the O
stimulation O
of O
transcription O
from O
the O
PEPCK B
promoter I
by O
2 O
3 O
- O
fold O
compared O
with O
wild B
type I
E1A I
. O

Mutations O
within O
conserved O
region O
2 O
( O
CR2 O
) O
of O
E1A B
that O
inhibit O
the O
binding O
of O
E1A B
to O
the O
retinoblastoma B
gene I
product I
( O
pRb B
) O
further O
enhanced O
the O
stimulation O
of O
transcription O
from O
the O
PEPCK B
promoter I
by O
2 O
3 O
- O
fold O
compared O
with O
wild B
type I
E1A I
. O

We O
used O
stored O
plasma O
samples O
from O
409 O
patients O
in O
the O
National O
Institute O
of O
Neurological O
Diseases O
and O
Stroke O
( O
NINDS O
) O
tissue B
plasminogen I
activator I
( O
t B
- I
PA I
) O
Stroke O
Trial O
to O
examine O
the O
relationship O
between O
an O
apolipoprotein B
( I
Apo I
) I
E2 I
or O
an O
Apo B
E4 I
phenotype O
and O
a O
favorable O
outcome O
3 O
months O
after O
stroke O
, O
the O
risk O
of O
intracerebral O
hemorrhage O
, O
and O
the O
response O
to O
intravenous O
t B
- I
PA I
therapy O
. O

We O
used O
stored O
plasma O
samples O
from O
409 O
patients O
in O
the O
National O
Institute O
of O
Neurological O
Diseases O
and O
Stroke O
( O
NINDS O
) O
tissue B
plasminogen I
activator I
( O
t B
- I
PA I
) O
Stroke O
Trial O
to O
examine O
the O
relationship O
between O
an O
apolipoprotein B
( I
Apo I
) I
E2 I
or O
an O
Apo B
E4 I
phenotype O
and O
a O
favorable O
outcome O
3 O
months O
after O
stroke O
, O
the O
risk O
of O
intracerebral O
hemorrhage O
, O
and O
the O
response O
to O
intravenous O
t B
- I
PA I
therapy O
. O

We O
used O
stored O
plasma O
samples O
from O
409 O
patients O
in O
the O
National O
Institute O
of O
Neurological O
Diseases O
and O
Stroke O
( O
NINDS O
) O
tissue B
plasminogen I
activator I
( O
t B
- I
PA I
) O
Stroke O
Trial O
to O
examine O
the O
relationship O
between O
an O
apolipoprotein B
( I
Apo I
) I
E2 I
or O
an O
Apo B
E4 I
phenotype O
and O
a O
favorable O
outcome O
3 O
months O
after O
stroke O
, O
the O
risk O
of O
intracerebral O
hemorrhage O
, O
and O
the O
response O
to O
intravenous O
t B
- I
PA I
therapy O
. O

Cytohesin B
- I
1 I
, O
a O
protein O
abundant O
in O
cells O
of O
the O
immune O
system O
, O
has O
been O
proposed O
to O
be O
a O
human O
homolog O
of O
the O
Saccharomyces B
cerevisiae I
Sec7 I
gene I
product I
, O
which O
is O
crucial O
in O
protein O
transport O
. O

The O
Lp B
mouse I
mutant I
provides O
a O
model O
for O
the O
severe O
human O
neural O
tube O
defect O
( O
NTD O
) O
, O
cranio O
- O
rachischisis O
. O

These O
results O
implicate O
a O
precursor O
- O
specific O
base O
- O
paired O
structure O
involving O
sequences O
on O
both O
sides O
of O
the O
mature O
cleavage O
site O
in O
the O
3 O
' O
processing O
of O
human B
U2 I
RNA I
. O

The O
discussion O
focuses O
primarily O
on O
the O
newer O
drugs O
like O
angiotensin B
converting I
enzyme I
inhibitors O
, O
alpha B
- I
adrenergic I
receptor I
blockers O
, O
and O
calcium O
antagonists O
. O

Substantial O
evidence O
supports O
a O
critical O
role O
for O
the O
activation O
of O
the O
Raf B
- I
1 I
/ O
MEK B
/ O
mitogen B
- I
activated I
protein I
kinase I
pathway O
in O
oncogenic O
Ras B
- O
mediated O
transformation O
. O

The O
amino O
acid O
sequence O
alignment O
of O
TC B
II I
with O
that O
of O
other O
Cbl B
binding I
proteins I
( O
rat B
intrinsic I
factor I
, O
human B
transcobalamin I
I I
and O
porcine B
haptocorrin I
) O
revealed O
only O
33 O
% O
overall O
homology O
. O

The O
amino O
acid O
sequence O
alignment O
of O
TC B
II I
with O
that O
of O
other O
Cbl B
binding I
proteins I
( O
rat B
intrinsic I
factor I
, O
human B
transcobalamin I
I I
and O
porcine B
haptocorrin I
) O
revealed O
only O
33 O
% O
overall O
homology O
. O

The O
amino O
acid O
sequence O
alignment O
of O
TC B
II I
with O
that O
of O
other O
Cbl B
binding I
proteins I
( O
rat B
intrinsic I
factor I
, O
human B
transcobalamin I
I I
and O
porcine B
haptocorrin I
) O
revealed O
only O
33 O
% O
overall O
homology O
. O

A O
reciprocal O
binding O
assay O
using O
IM O
- O
9 O
cells O
as O
a O
source O
of O
SHP B
- I
1 I
and O
SHP B
- I
2 I
revealed O
specific O
association O
of O
SHP B
- I
2 I
( O
but O
not O
SHP B
- I
1 I
) O
with O
a O
glutathione B
S I
- I
transferase I
fusion I
incorporating O
GHR B
cytoplasmic I
domain I
residues I
485 I
- I
620 I
, O
but O
only O
if O
the O
fusion O
was O
first O
rendered O
tyrosine O
- O
phosphorylated O
. O

A O
reciprocal O
binding O
assay O
using O
IM O
- O
9 O
cells O
as O
a O
source O
of O
SHP B
- I
1 I
and O
SHP B
- I
2 I
revealed O
specific O
association O
of O
SHP B
- I
2 I
( O
but O
not O
SHP B
- I
1 I
) O
with O
a O
glutathione B
S I
- I
transferase I
fusion I
incorporating O
GHR B
cytoplasmic I
domain I
residues I
485 I
- I
620 I
, O
but O
only O
if O
the O
fusion O
was O
first O
rendered O
tyrosine O
- O
phosphorylated O
. O

A O
reciprocal O
binding O
assay O
using O
IM O
- O
9 O
cells O
as O
a O
source O
of O
SHP B
- I
1 I
and O
SHP B
- I
2 I
revealed O
specific O
association O
of O
SHP B
- I
2 I
( O
but O
not O
SHP B
- I
1 I
) O
with O
a O
glutathione B
S I
- I
transferase I
fusion I
incorporating O
GHR B
cytoplasmic I
domain I
residues I
485 I
- I
620 I
, O
but O
only O
if O
the O
fusion O
was O
first O
rendered O
tyrosine O
- O
phosphorylated O
. O

A O
reciprocal O
binding O
assay O
using O
IM O
- O
9 O
cells O
as O
a O
source O
of O
SHP B
- I
1 I
and O
SHP B
- I
2 I
revealed O
specific O
association O
of O
SHP B
- I
2 I
( O
but O
not O
SHP B
- I
1 I
) O
with O
a O
glutathione B
S I
- I
transferase I
fusion I
incorporating O
GHR B
cytoplasmic I
domain I
residues I
485 I
- I
620 I
, O
but O
only O
if O
the O
fusion O
was O
first O
rendered O
tyrosine O
- O
phosphorylated O
. O

Insulin B
- I
like I
growth I
factor I
1 I
( O
IGF B
- I
1 I
) O
in O
burn O
patients O
. O

Abrogation O
of O
p53 B
function O
by O
E6 B
resulted O
in O
an O
increase O
in O
the O
spontaneous O
mutation O
frequencies O
at O
the O
heterozygous O
thymidine B
kinase I
( O
TK B
) O
locus O
but O
not O
at O
the O
hemizygous O
hypoxanthine B
phosphoribosyl I
transferase I
( O
HPRT B
) O
locus O
. O

In O
view O
of O
the O
presence O
of O
SECIS O
elements O
in O
the O
open O
reading O
frames O
( O
ORFs O
) O
of O
bacterial B
selenoproteins I
, O
we O
examine O
the O
effects O
in O
the O
type B
1 I
deiodinase I
of O
extending O
the O
ORF O
into O
the O
SECIS O
element O
, O
and O
find O
that O
this O
dramatically O
inhibits O
SECIS O
function O
. O

A O
second O
important O
molecule O
in O
TCR B
signal O
transduction O
is O
the O
guanine B
nucleotide I
binding I
protein I
, O
p21ras B
, O
which O
is O
coupled O
to O
the O
TCR B
by O
a O
protein B
tyrosine I
kinase I
dependent O
mechanism O
. O

The O
contribution O
that O
alternative O
splicing O
events O
in O
c B
- I
myb I
expression O
may O
make O
on O
c B
- I
myb I
function O
remains O
to O
be O
elucidated O
. O

The O
contribution O
that O
alternative O
splicing O
events O
in O
c B
- I
myb I
expression O
may O
make O
on O
c B
- I
myb I
function O
remains O
to O
be O
elucidated O
. O

The O
Nostoc O
petBD B
genes I
are O
not O
closely O
linked O
to O
the O
psbB B
gene I
( O
encoding O
the O
51 O
- O
kDa O
photosystem B
II I
polypeptide I
) O
and O
do O
not O
contain O
introns O
as O
do O
the O
closely O
related O
chloroplast O
genes O
. O

A O
subset O
of O
these O
DMP1 B
recognition I
sequences I
containing O
a O
GGA O
trinucleotide O
core O
can O
also O
function O
as O
Ets B
- I
responsive I
elements I
. O

However O
, O
by O
immobilized O
metal O
affinity O
chromatography O
assay O
, O
self O
- O
association O
of O
PR B
- I
A I
was O
3 O
. O
5 O
- O
fold O
more O
efficient O
than O
that O
of O
either O
the O
DhLBD O
or O
hLBD O
constructs O
. O

A O
20 O
- O
base O
pair O
oligonucleotide O
containing O
this O
nonamer O
confers O
up O
- O
regulation O
by O
hypoxia O
and O
inhibition O
by O
unsaturated O
fatty O
acids O
when O
placed O
upstream O
of O
a O
heterologous O
promoter O
in O
a O
lacZ B
reporter I
construct I
. O

The O
MET4 B
gene O
was O
cloned O
, O
and O
its O
sequence O
reveals O
that O
it O
encodes O
a O
protein O
related O
to O
the O
family O
of O
the O
bZIP B
transcriptional I
activators I
. O

Tumor B
necrosis I
factor I
signaling O
to O
stress B
- I
activated I
protein I
kinase I
( O
SAPK B
) O
/ O
Jun B
NH2 I
- I
terminal I
kinase I
( O
JNK B
) O
and O
p38 B
. O

AMY B
- I
1 I
was O
localized O
in O
the O
cytoplasm O
in O
cells O
expressing O
c B
- I
myc I
at O
low O
levels O
, O
but O
in O
the O
nucleus O
in O
the O
cells O
of O
a O
high O
c B
- I
myc I
expression O
in O
transiently O
transfected O
cells O
. O

AMY B
- I
1 I
was O
localized O
in O
the O
cytoplasm O
in O
cells O
expressing O
c B
- I
myc I
at O
low O
levels O
, O
but O
in O
the O
nucleus O
in O
the O
cells O
of O
a O
high O
c B
- I
myc I
expression O
in O
transiently O
transfected O
cells O
. O

AMY B
- I
1 I
was O
localized O
in O
the O
cytoplasm O
in O
cells O
expressing O
c B
- I
myc I
at O
low O
levels O
, O
but O
in O
the O
nucleus O
in O
the O
cells O
of O
a O
high O
c B
- I
myc I
expression O
in O
transiently O
transfected O
cells O
. O

This O
region O
of O
hsp90 B
mediates O
ATP O
- O
independent O
chaperone O
activity O
, O
overlaps O
the O
hsp90 B
dimerization I
domain I
, O
and O
includes O
structural O
elements O
important O
for O
steroid B
receptor I
interaction O
. O

Serum B
insulin I
- I
like I
growth I
factor I
I I
( O
IGF B
- I
I I
) O
SD O
score O
increased O
from O
- O
2 O
. O
2 O
and O
- O
4 O
. O
2 O
in O
men O
and O
women O
, O
respectively O
, O
to O
1 O
. O
8 O
and O
- O
0 O
. O
9 O
at O
6 O
months O
and O
0 O
. O
8 O
and O
- O
0 O
. O
7 O
at O
12 O
months O
. O

The O
effect O
of O
nitric B
oxide I
synthase I
inhibitor O
on O
reperfusion O
injury O
of O
the O
brain O
under O
hypothermic O
circulatory O
arrest O
. O

The O
role O
of O
DNA O
rearrangement O
and O
alternative O
RNA O
processing O
in O
the O
expression O
of O
immunoglobulin B
delta I
genes I
. O

Blood O
GSH B
- I
Px I
activity O
was O
measured O
with O
a O
spectrophotometer O
, O
using O
a O
modification O
of O
a O
previously O
described O
assay O
. O

Based O
on O
the O
current O
literature O
, O
the O
mechanisms O
involved O
in O
the O
toxicity O
of O
OA B
indicate O
three O
major O
effects O
: O
( O
1 O
) O
inhibition O
of O
mitochondrial O
respiration O
correlated O
with O
a O
depletion O
of O
ATP O
; O
( O
2 O
) O
inhibition O
of O
tRNA B
- I
synthetase I
accompanied O
by O
a O
reduced O
protein O
synthesis O
; O
and O
( O
3 O
) O
enhanced O
lipid O
peroxidation O
. O

SRE O
activity O
is O
dependent O
upon O
the O
activation O
by O
phosphorylation O
of O
a O
ternary O
complex O
factor O
; O
included O
among O
the O
ternary O
complex O
factors O
is O
Elk B
- I
1 I
. O

INTERVENTIONS O
: O
Patients O
received O
rt B
- I
PA I
, O
heparin O
, O
and O
aspirin O
. O

UDP B
- I
GlcNAc I
: O
alpha B
- I
6 I
- I
D I
- I
mannoside I
beta I
- I
1 I
, I
2 I
- I
N I
- I
acetylglucosaminyltransferase I
II I
( O
GnT B
II I
; O
EC B
2 I
. I
4 I
. I
1 I
. I
143 I
) O
is O
essential O
for O
the O
normal O
assembly O
of O
complex O
Asn O
- O
linked O
glycans O
. O

The O
p130 B
and O
p62 B
tyrosine O
- O
phosphorylated O
proteins O
that O
complexed O
v B
- I
Src I
SH2 B
in O
vitro O
also O
associated O
with O
v B
- I
Src I
in O
v B
- I
src I
- O
transformed O
Rat O
- O
2 O
cells O
; O
this O
in O
vivo O
binding O
was O
dependent O
on O
the O
v B
- I
Src I
SH2 B
domain O
. O

The O
p130 B
and O
p62 B
tyrosine O
- O
phosphorylated O
proteins O
that O
complexed O
v B
- I
Src I
SH2 B
in O
vitro O
also O
associated O
with O
v B
- I
Src I
in O
v B
- I
src I
- O
transformed O
Rat O
- O
2 O
cells O
; O
this O
in O
vivo O
binding O
was O
dependent O
on O
the O
v B
- I
Src I
SH2 B
domain O
. O

The O
p130 B
and O
p62 B
tyrosine O
- O
phosphorylated O
proteins O
that O
complexed O
v B
- I
Src I
SH2 B
in O
vitro O
also O
associated O
with O
v B
- I
Src I
in O
v B
- I
src I
- O
transformed O
Rat O
- O
2 O
cells O
; O
this O
in O
vivo O
binding O
was O
dependent O
on O
the O
v B
- I
Src I
SH2 B
domain O
. O

The O
p130 B
and O
p62 B
tyrosine O
- O
phosphorylated O
proteins O
that O
complexed O
v B
- I
Src I
SH2 B
in O
vitro O
also O
associated O
with O
v B
- I
Src I
in O
v B
- I
src I
- O
transformed O
Rat O
- O
2 O
cells O
; O
this O
in O
vivo O
binding O
was O
dependent O
on O
the O
v B
- I
Src I
SH2 B
domain O
. O

Previously O
, O
we O
showed O
that O
the O
APRE O
is O
a O
cytokine O
[ O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNFalpha B
) O
] O
- O
inducible O
enhancer O
by O
binding O
the O
heterodimeric B
nuclear I
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
complex O
Rel B
A I
x O
NF B
- I
kappaB1 I
. O

Previously O
, O
we O
showed O
that O
the O
APRE O
is O
a O
cytokine O
[ O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNFalpha B
) O
] O
- O
inducible O
enhancer O
by O
binding O
the O
heterodimeric B
nuclear I
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
complex O
Rel B
A I
x O
NF B
- I
kappaB1 I
. O

PRL B
- I
1 I
is O
able O
to O
dephosphorylate O
phosphotyrosine O
substrates O
, O
and O
mutation O
of O
the O
active O
- O
site O
cysteine O
residue O
abolishes O
this O
activity O
. O

The O
gene O
is O
1 O
, O
139 O
base O
pairs O
( O
bp O
) O
long O
, O
and O
, O
like O
other O
members O
of O
the O
SIG B
family I
, O
the O
beta B
TG I
gene I
is O
divided O
into O
3 O
exons O
. O

Using O
a O
conditional O
- O
lethal O
mutant O
allele O
of O
SUP45 B
( O
sup45 B
- I
2 I
) O
and O
a O
combination O
of O
in O
vivo O
and O
in O
vitro O
approaches O
, O
we O
demonstrate O
that O
the O
product O
of O
the O
SUP45 B
gene I
( O
Sup45p B
or O
eRF1 B
) O
is O
a O
factor O
required O
for O
translation O
termination O
in O
yeast O
. O

The O
5 O
' O
- O
terminus O
of O
the O
p B
- I
gvpF I
- I
M I
mRNA I
was O
located O
169 O
nucleotides O
upstream O
of O
p B
- I
gvpF I
within O
p B
- I
gvpE I
. O

The O
5 O
' O
- O
terminus O
of O
the O
p B
- I
gvpF I
- I
M I
mRNA I
was O
located O
169 O
nucleotides O
upstream O
of O
p B
- I
gvpF I
within O
p B
- I
gvpE I
. O

We O
also O
isolated O
two O
alternatively O
spliced O
forms O
of O
human B
CD6 I
cDNA I
lacking O
sequences O
encoding O
membrane O
- O
proximal O
regions O
of O
the O
cytoplasmic O
domain O
which O
maintain O
the O
same O
reading O
frame O
as O
CD6 B
- O
PB1 B
. O

This O
revealed O
a O
minimum O
of O
six O
novel O
OSBP B
- I
related I
proteins I
, O
designated O
ORP B
- I
1 I
to O
ORP B
- I
6 I
. O

This O
revealed O
a O
minimum O
of O
six O
novel O
OSBP B
- I
related I
proteins I
, O
designated O
ORP B
- I
1 I
to O
ORP B
- I
6 I
. O

These O
results O
further O
support O
an O
important O
role O
for O
CBF2 B
in O
mediating O
EBNA2 B
transactivation O
; O
they O
identify O
the O
hnRNP B
protein I
AUF1 I
as O
a O
major O
component O
of O
CBF2 B
and O
are O
also O
the O
first O
evidence O
of O
a O
cis O
- O
acting O
sequence O
other O
than O
a O
CBF1 B
binding I
element I
that O
is O
able O
to O
confer O
responsiveness O
to O
EBNA2 B
. O

These O
results O
further O
support O
an O
important O
role O
for O
CBF2 B
in O
mediating O
EBNA2 B
transactivation O
; O
they O
identify O
the O
hnRNP B
protein I
AUF1 I
as O
a O
major O
component O
of O
CBF2 B
and O
are O
also O
the O
first O
evidence O
of O
a O
cis O
- O
acting O
sequence O
other O
than O
a O
CBF1 B
binding I
element I
that O
is O
able O
to O
confer O
responsiveness O
to O
EBNA2 B
. O

Furthermore O
, O
competitor O
containing O
the O
YY1 B
consensus I
sequence I
competed O
for O
protein B
B I
binding O
, O
whereas O
competitor O
containing O
a O
perfect O
yeast B
ABF I
- I
1 I
consensus I
sequence I
did O
not O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

Diverse O
endogenous O
light O
chains O
contribute O
to O
basement O
membrane O
reactivity O
in O
nonautoimmune O
mice O
transgenic O
for O
an O
anti B
- I
laminin I
Ig B
heavy I
chain I
. O

Diverse O
endogenous O
light O
chains O
contribute O
to O
basement O
membrane O
reactivity O
in O
nonautoimmune O
mice O
transgenic O
for O
an O
anti B
- I
laminin I
Ig B
heavy I
chain I
. O

At O
the O
C O
- O
terminus O
of O
the O
protein O
is O
a O
domain O
that O
contains O
sequences O
very O
similar O
to O
those O
found O
in O
the O
breakpoint O
cluster O
region O
gene O
product O
, O
n B
- I
chimerin I
, O
and O
rho B
GAP I
, O
all O
of O
which O
have O
been O
shown O
to O
possess O
intrinsic O
GAP B
activity O
on O
small B
GTPases I
. O

Studies O
were O
performed O
on O
several O
superficial O
veins O
from O
the O
rabbit O
face O
to O
examine O
the O
relationship O
between O
beta B
adrenoceptor I
subtype I
distribution O
, O
intrinsic O
myogenic O
tone O
and O
sympathetic O
nerve O
innervation O
. O

RT O
- O
PCR O
analysis O
showed O
that O
PLP B
- I
H I
as O
well O
as O
PLP B
- I
C I
and O
PLP B
- I
D I
are O
expressed O
in O
all O
rat O
strains O
examined O
, O
confirming O
that O
PLP B
diversity O
is O
not O
due O
to O
strain O
differences O
. O

RT O
- O
PCR O
analysis O
showed O
that O
PLP B
- I
H I
as O
well O
as O
PLP B
- I
C I
and O
PLP B
- I
D I
are O
expressed O
in O
all O
rat O
strains O
examined O
, O
confirming O
that O
PLP B
diversity O
is O
not O
due O
to O
strain O
differences O
. O

RT O
- O
PCR O
analysis O
showed O
that O
PLP B
- I
H I
as O
well O
as O
PLP B
- I
C I
and O
PLP B
- I
D I
are O
expressed O
in O
all O
rat O
strains O
examined O
, O
confirming O
that O
PLP B
diversity O
is O
not O
due O
to O
strain O
differences O
. O

Thus O
, O
the O
human B
D1A I
gene I
belongs O
to O
the O
category O
of O
tissue O
- O
specific O
, O
regulated O
genes O
that O
have O
housekeeping O
- O
type O
promoters O
. O

In O
Rat O
1a O
cells O
, O
m1R B
stimulation O
of O
phospholipase B
C I
beta I
and O
the O
marked O
rise O
in O
intracellular O
calcium O
stimulated O
cyclic O
AMP O
( O
cAMP O
) O
synthesis O
, O
resulting O
in O
the O
activation O
of O
protein B
kinase I
A I
. O

In O
Rat O
1a O
cells O
, O
m1R B
stimulation O
of O
phospholipase B
C I
beta I
and O
the O
marked O
rise O
in O
intracellular O
calcium O
stimulated O
cyclic O
AMP O
( O
cAMP O
) O
synthesis O
, O
resulting O
in O
the O
activation O
of O
protein B
kinase I
A I
. O

Regulation O
of O
irgA B
by O
iron O
in O
V O
. O
cholerae O
occurs O
at O
the O
transcriptional O
level O
, O
and O
there O
is O
an O
interrupted O
dyad O
symmetric O
sequence O
in O
the O
vicinity O
of O
the O
promoter O
that O
is O
homologous O
to O
Fur B
binding I
sites I
of O
E O
. O
coli O
. O

We O
recently O
characterized O
a O
single O
yeast B
hnRNP I
methyltransferase I
( O
HMT1 B
) O
. O

We O
recently O
characterized O
a O
single O
yeast B
hnRNP I
methyltransferase I
( O
HMT1 B
) O
. O

We O
then O
demonstrated O
that O
1 O
) O
GAL4 B
- O
REV B
- O
erbA B
alpha I
chimeras O
that O
contain O
the O
' O
AB O
' O
region O
and O
lack O
the O
' O
E O
' O
region O
activated O
transcription O
of O
GAL4 B
response I
elements I
in O
the O
presence O
of O
8 O
- O
Br O
- O
cAMP O
and O
2 O
) O
the O
ligand O
- O
binding O
domain O
( O
LBD O
) O
contains O
an O
active O
transcriptional O
silencer O
. O

We O
also O
show O
that O
activation O
of O
protein B
kinase I
A I
( O
PKA B
) O
signaling O
is O
sufficient O
to O
down O
- O
regulate O
caveolin B
- I
1 I
protein I
expression O
and O
promoter O
activity O
. O

A O
xylE B
transcriptional I
fusion I
to O
the O
putative O
mxbD B
promoter I
showed O
low O
- O
level O
expression O
in O
wild O
- O
type O
cells O
grown O
on O
one O
- O
carbon O
( O
C1 O
) O
compounds O
and O
no O
detectable O
expression O
in O
cells O
grown O
on O
succinate O
. O

Heat O
- O
labile O
- O
like O
enterotoxin O
( O
LT B
) O
was O
produced O
by O
26 O
of O
42 O
stool O
isolates O
( O
62 O
% O
) O
, O
while O
only O
1 O
of O
the O
42 O
isolates O
( O
2 O
% O
) O
produced O
enterotoxinlike O
activity O
in O
suckling O
mice O
; O
65 O
% O
of O
the O
cytotoxin O
- O
producing O
strains O
also O
produced O
an O
LT B
- I
like I
material O
. O

In O
the O
present O
study O
, O
we O
show O
that O
SRm160 B
/ I
300 I
is O
required O
for O
a O
purine O
- O
rich O
ESE B
to O
promote O
the O
splicing O
of O
a O
pre O
- O
mRNA O
derived O
from O
the O
Drosophila B
doublesex I
gene I
. O

In O
the O
present O
study O
, O
we O
show O
that O
SRm160 B
/ I
300 I
is O
required O
for O
a O
purine O
- O
rich O
ESE B
to O
promote O
the O
splicing O
of O
a O
pre O
- O
mRNA O
derived O
from O
the O
Drosophila B
doublesex I
gene I
. O

In O
adherent O
macrophages O
, O
absence O
of O
CD45 B
led O
to O
the O
hyperphosphorylation O
and O
hyperactivation O
of O
p56 B
/ I
59 I
( O
hck B
) O
and O
p53 B
/ I
56 I
( O
lyn B
) O
, O
but O
not O
of O
p58 B
( O
c B
- I
fgr I
) O
. O

In O
adherent O
macrophages O
, O
absence O
of O
CD45 B
led O
to O
the O
hyperphosphorylation O
and O
hyperactivation O
of O
p56 B
/ I
59 I
( O
hck B
) O
and O
p53 B
/ I
56 I
( O
lyn B
) O
, O
but O
not O
of O
p58 B
( O
c B
- I
fgr I
) O
. O

In O
adherent O
macrophages O
, O
absence O
of O
CD45 B
led O
to O
the O
hyperphosphorylation O
and O
hyperactivation O
of O
p56 B
/ I
59 I
( O
hck B
) O
and O
p53 B
/ I
56 I
( O
lyn B
) O
, O
but O
not O
of O
p58 B
( O
c B
- I
fgr I
) O
. O

Cloning O
of O
a O
human O
cDNA O
encoding O
a O
CDC2 B
- I
related I
kinase I
by O
complementation O
of O
a O
budding B
yeast I
cdc28 I
mutation O
. O

Peroxisome B
proliferator I
- I
activated I
receptors I
( O
PPARs B
) O
and O
retinoid B
X I
receptors I
( O
RXRs B
) O
are O
nuclear B
hormone I
receptors I
that O
are O
activated O
by O
fatty O
acids O
and O
9 O
- O
cis O
- O
retinoic O
acid O
, O
respectively O
. O

Peroxisome B
proliferator I
- I
activated I
receptors I
( O
PPARs B
) O
and O
retinoid B
X I
receptors I
( O
RXRs B
) O
are O
nuclear B
hormone I
receptors I
that O
are O
activated O
by O
fatty O
acids O
and O
9 O
- O
cis O
- O
retinoic O
acid O
, O
respectively O
. O

We O
had O
previously O
analyzed O
repair O
rates O
of O
cyclobutane O
pyrimidine O
dimers O
at O
nucleotide O
resolution O
along O
the O
human B
JUN I
gene I
in O
normal O
fibroblasts O
and O
found O
very O
efficient O
repair O
of O
sequences O
near O
the O
transcription O
initiation O
site O
but O
slow O
repair O
along O
the O
promoter O
. O

Analysis O
of O
regulatory O
regions O
in O
the O
promoter O
of O
the O
ctr4 B
( I
+ I
) I
copper I
transporter I
gene I
in O
fission O
yeast O
Schizosaccharomyces O
pombe O
reveals O
the O
identity O
of O
a O
conserved O
copper O
- O
signaling O
element O
( O
CuSE O
) O
, O
which O
is O
recognized O
by O
the O
transcription B
factor I
Cuf1 I
. O

RVR B
' O
loss O
of O
function O
' O
studies O
by O
constitutive O
over O
- O
expression O
of O
a O
dominant O
negative O
RVR B
delta I
E I
resulted O
in O
increased O
levels O
of O
p21Cip1 B
/ O
Waf1 B
and O
myogenin B
mRNAs I
after O
serum O
withdrawal O
. O

Splicing O
of O
the O
K B
- I
SAM I
alternative O
exon O
of O
the O
fibroblast B
growth I
factor I
receptor I
2 I
gene I
is O
heavily O
dependent O
on O
the O
U O
- O
rich O
sequence O
IAS1 B
lying O
immediately O
downstream O
from O
its O
5 O
' O
splice O
site O
. O

Our O
data O
demonstrate O
directly O
that O
Rpm1r B
is O
transcribed O
with O
its O
substrates O
, O
tRNA B
met I
f I
and O
tRNAPro B
, O
from O
a O
promoter O
located O
upstream O
of O
the O
tRNA B
met I
f I
gene I
and O
suggest O
that O
a O
portion O
also O
originates O
from O
a O
second O
promoter O
, O
located O
between O
the O
tRNA B
met I
f I
gene I
and O
RPM1 B
. O

Alternatively O
, O
PC12 O
- O
E2 O
cells O
were O
submitted O
to O
treatment O
with O
antibodies O
to O
the O
fibroblast B
growth I
factor I
( I
FGF I
) I
receptor I
, O
inhibitors O
of O
the O
nonreceptor B
tyrosine I
kinase I
p59 B
( O
fyn B
) O
, O
PLC B
, O
PKC B
and O
MEK B
and O
an O
activator O
of O
PKC B
, O
phorbol O
- O
12 O
- O
myristate O
- O
13 O
- O
acetate O
( O
PMA O
) O
. O

We O
have O
previously O
identified O
, O
by O
screening O
a O
lambda O
gt11 O
expression O
library O
, O
murine B
protein I
mXBP I
, O
which O
binds O
to O
a O
sequence O
which O
overlaps O
the O
3 O
' O
end O
of O
the O
murine B
class I
II I
major I
histocompatibility I
complex I
A I
alpha I
gene I
X I
box I
, O
a O
conserved O
transcription O
element O
found O
upstream O
of O
all O
class O
II O
genes O
. O

Cyclin B
- I
dependent I
kinase I
- I
2 I
( O
Cdk2 B
) O
forms O
an O
inactive O
complex O
with O
cyclin B
D1 I
since O
Cdk2 B
associated O
with O
cyclin B
D1 I
is O
not O
phosphorylated O
by O
Cdk7 B
- O
cyclin B
- I
H I
. O

Liver O
transplantation O
in O
one O
patient O
resolved O
metabolic O
complications O
but O
did O
not O
improve O
PMN O
count O
or O
the O
infectious O
status O
, O
while O
neutropenia O
was O
corrected O
by O
G B
- I
CSF I
. O

According O
to O
the O
published O
sequence O
of O
the O
CHS1 B
gene I
, O
this O
fragment O
contains O
four O
repeats O
of O
a O
TGAAACA O
consensus O
sequence O
previously O
identified O
in O
the O
alpha B
- I
factor I
- O
inducible O
BAR1 B
promoter I
[ O
Kronstad O
, O
J O
. O

The O
results O
suggest O
that O
GATA B
- I
5 I
may O
have O
specific O
downstream O
targets O
and O
that O
GATA B
- I
4 I
, I
- I
5 I
, I
and I
- I
6 I
can O
only O
partially O
substitute O
for O
each O
other O
in O
cardiogenesis O
. O

The O
epidermal B
growth I
factor I
( I
EGF I
) I
receptor I
, O
which O
exhibits O
intrinsic O
protein B
tyrosine I
kinase I
activity O
, O
undergoes O
a O
rapid O
, O
intramolecular O
self O
- O
phosphorylation O
reaction O
following O
EGF B
activation O
. O

The O
data O
indicate O
that O
etr B
- I
1 I
is O
essential O
for O
muscle O
development O
in O
C O
. O
elegans O
, O
perhaps O
by O
playing O
a O
role O
in O
post O
- O
transcriptional O
processing O
of O
some O
muscle O
component O
, O
and O
thus O
suggesting O
a O
possible O
conservation O
of O
gene O
function O
with O
human B
CUG I
- I
bp I
. O

Examination O
of O
immediate B
- I
early I
transcription I
factor I
expression O
during O
the O
MDI O
regimen O
revealed O
that O
RA O
mediated O
an O
elevated O
, O
prolonged O
expression O
of O
c B
- I
Jun I
mRNA I
accompanied O
by O
diminished O
expression O
of O
c B
- I
Fos I
and O
Jun B
- I
B I
mRNAs I
. O

These O
cells O
fail O
to O
generate O
the O
signals O
to O
phosphorylate O
CREB B
and O
produce O
significantly O
less O
of O
the O
cytokine O
Interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
in O
response O
to O
agents O
that O
either O
increase O
intracellular O
Ca2 O
+ O
and O
/ O
or O
activate O
protein B
kinase I
C I
. O

These O
cells O
fail O
to O
generate O
the O
signals O
to O
phosphorylate O
CREB B
and O
produce O
significantly O
less O
of O
the O
cytokine O
Interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
in O
response O
to O
agents O
that O
either O
increase O
intracellular O
Ca2 O
+ O
and O
/ O
or O
activate O
protein B
kinase I
C I
. O

These O
cells O
fail O
to O
generate O
the O
signals O
to O
phosphorylate O
CREB B
and O
produce O
significantly O
less O
of O
the O
cytokine O
Interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
in O
response O
to O
agents O
that O
either O
increase O
intracellular O
Ca2 O
+ O
and O
/ O
or O
activate O
protein B
kinase I
C I
. O

The O
human B
ABCG1 I
gene I
encodes O
a O
member O
of O
the O
ATP B
- I
binding I
cassette I
( O
ABC B
) O
superfamily O
of O
transporter B
proteins I
and O
is O
highly O
induced O
when O
macrophages O
are O
incubated O
with O
oxysterols O
. O

RNA O
gel O
retardation O
and O
competition O
analyses O
indicate O
that O
TRP B
- I
185 I
binding O
is O
strongly O
dependent O
on O
the O
TAR O
RNA O
loop O
sequences O
. O

Altogether O
these O
results O
suggest O
that O
, O
in O
KG1a O
cells O
, O
TNFalpha B
can O
stimulate O
in O
parallel O
PC B
- I
PLC I
and O
PLD B
, O
whose O
lipid O
products O
activate O
in O
turn O
mitogen B
- I
activated I
protein I
kinase I
( O
MAP B
kinase I
) O
and O
NF B
- I
kappaB I
signalling O
respectively O
. O

Altogether O
these O
results O
suggest O
that O
, O
in O
KG1a O
cells O
, O
TNFalpha B
can O
stimulate O
in O
parallel O
PC B
- I
PLC I
and O
PLD B
, O
whose O
lipid O
products O
activate O
in O
turn O
mitogen B
- I
activated I
protein I
kinase I
( O
MAP B
kinase I
) O
and O
NF B
- I
kappaB I
signalling O
respectively O
. O

The O
RI B
alpha I
gene I
is O
composed O
of O
nine O
coding O
exons O
of O
varying O
lengths O
, O
separated O
by O
introns O
, O
giving O
the O
gene O
a O
total O
length O
of O
at O
least O
21 O
kb O
. O
our O
recent O
cloning O
of O
a O
processed O
RI B
alpha I
pseudogene I
with O
a O
5 O
' O
- O
noncoding O
region O
different O
from O
the O
previously O
reported O
RI B
alpha I
complementary I
RNA I
indicated O
that O
the O
RI B
alpha I
gene I
may O
have O
multiple O
leader O
exons O
giving O
rise O
to O
alternately O
spliced O
messenger O
RNAs O
( O
mRNAs O
) O
. O

The O
RI B
alpha I
gene I
is O
composed O
of O
nine O
coding O
exons O
of O
varying O
lengths O
, O
separated O
by O
introns O
, O
giving O
the O
gene O
a O
total O
length O
of O
at O
least O
21 O
kb O
. O
our O
recent O
cloning O
of O
a O
processed O
RI B
alpha I
pseudogene I
with O
a O
5 O
' O
- O
noncoding O
region O
different O
from O
the O
previously O
reported O
RI B
alpha I
complementary I
RNA I
indicated O
that O
the O
RI B
alpha I
gene I
may O
have O
multiple O
leader O
exons O
giving O
rise O
to O
alternately O
spliced O
messenger O
RNAs O
( O
mRNAs O
) O
. O

The O
RI B
alpha I
gene I
is O
composed O
of O
nine O
coding O
exons O
of O
varying O
lengths O
, O
separated O
by O
introns O
, O
giving O
the O
gene O
a O
total O
length O
of O
at O
least O
21 O
kb O
. O
our O
recent O
cloning O
of O
a O
processed O
RI B
alpha I
pseudogene I
with O
a O
5 O
' O
- O
noncoding O
region O
different O
from O
the O
previously O
reported O
RI B
alpha I
complementary I
RNA I
indicated O
that O
the O
RI B
alpha I
gene I
may O
have O
multiple O
leader O
exons O
giving O
rise O
to O
alternately O
spliced O
messenger O
RNAs O
( O
mRNAs O
) O
. O

While O
mutations O
in O
K B
- I
Rev I
that O
inactivate O
any O
one O
of O
these O
properties O
also O
blocked O
K B
- I
Rev I
- O
dependent O
nuclear O
RNA O
export O
, O
several O
K B
- I
Rev I
mutants I
were O
comparable O
to O
wild O
type O
when O
assayed O
for O
any O
of O
these O
individual O
activities O
yet O
nevertheless O
defective O
for O
RNA O
export O
. O

While O
mutations O
in O
K B
- I
Rev I
that O
inactivate O
any O
one O
of O
these O
properties O
also O
blocked O
K B
- I
Rev I
- O
dependent O
nuclear O
RNA O
export O
, O
several O
K B
- I
Rev I
mutants I
were O
comparable O
to O
wild O
type O
when O
assayed O
for O
any O
of O
these O
individual O
activities O
yet O
nevertheless O
defective O
for O
RNA O
export O
. O

Tissue B
plasminogen I
activator I
, O
its O
inhibitor O
and O
other O
parameters O
of O
fibrinolysis O
in O
blood O
of O
patients O
operated O
for O
mild O
hypertrophy O
of O
the O
prostate O

The O
STAT B
- I
1 I
signaling O
pathway O
provides O
at O
least O
one O
mechanism O
for O
activation O
of O
the O
CAEV B
LTR I
by O
IFN B
- I
gamma I
in O
monocytes O
. O

The O
STAT B
- I
1 I
signaling O
pathway O
provides O
at O
least O
one O
mechanism O
for O
activation O
of O
the O
CAEV B
LTR I
by O
IFN B
- I
gamma I
in O
monocytes O
. O

Pax B
- I
3 I
is O
a O
paired B
- I
type I
homeobox I
gene I
that O
is O
specifically O
expressed O
in O
the O
dorsal O
and O
posterior O
neural O
tube O
. O

We O
show O
here O
that O
the O
in O
vitro O
transcription O
extract O
contains O
a O
binding O
activity O
that O
is O
specific O
for O
the O
initiator O
element O
and O
thus O
may O
participate O
in O
recruiting O
RNA B
polymerase I
II I
to O
the O
SL O
RNA O
gene O
promoter O
. O

The O
reduced O
NO O
production O
in O
these O
cells O
was O
associated O
with O
low O
levels O
of O
mRNA O
of O
inducible B
NO I
synthetase I
. O

Sequence O
analysis O
of O
the O
isolated O
genomic O
clone O
revealed O
that O
the O
DNA O
binding O
domain O
of O
this O
orphan O
receptor O
is O
most O
homologous O
to O
the O
human B
TR2 I
receptor I
. O

Mutational O
analysis O
of O
mRNA B
capping I
enzyme I
identifies O
amino O
acids O
involved O
in O
GTP O
binding O
, O
enzyme O
- O
guanylate O
formation O
, O
and O
GMP O
transfer O
to O
RNA O
. O

TNFalpha B
and O
IL B
- I
6 I
levels O
were O
determined O
in O
the O
culture O
supernatants O
. O

Using O
adenoviral O
transfer O
of O
IkappaBalpha B
( O
IkappaBalpha B
overexpression O
) O
, O
the O
production O
of O
TNF B
- I
alpha I
induced O
by O
whole O
GBS O
was O
inhibited O
by O
only O
20 O
% O
. O

Two O
putative O
Rev B
proteins I
with O
apparent O
molecular O
masses O
of O
18 O
and O
16 O
kDa O
were O
expressed O
by O
p2 B
/ I
2 I
and O
p176 B
, O
while O
p20 B
expressed O
only O
a O
16 O
- O
kDa O
species O
. O

TaqMan O
analysis O
of O
gene O
expression O
following O
chronic O
FA O
treatment O
showed O
neither O
a O
decrease O
in O
the O
amount O
of O
leptin B
receptor I
( O
Ob B
- I
R I
) O
mRNA O
, O
nor O
an O
increase O
in O
the O
negative O
regulators O
of O
STAT B
signalling O
, O
SOCS3 B
( O
suppressors B
of I
cytokine I
signalling I
) O
or O
cytokine B
inducible I
sequence I
( O
CIS B
) O
. O

TaqMan O
analysis O
of O
gene O
expression O
following O
chronic O
FA O
treatment O
showed O
neither O
a O
decrease O
in O
the O
amount O
of O
leptin B
receptor I
( O
Ob B
- I
R I
) O
mRNA O
, O
nor O
an O
increase O
in O
the O
negative O
regulators O
of O
STAT B
signalling O
, O
SOCS3 B
( O
suppressors B
of I
cytokine I
signalling I
) O
or O
cytokine B
inducible I
sequence I
( O
CIS B
) O
. O

Overexpression O
of O
BAG B
- I
1 I
also O
protected O
certain O
cell O
lines O
from O
heat O
shock O
- O
induced O
cell O
death O
. O

Coronary O
vasoconstriction O
caused O
by O
endothelin B
- I
1 I
is O
enhanced O
by O
ischemia O
- O
reperfusion O
and O
by O
norepinephrine O
present O
in O
concentrations O
typically O
observed O
after O
neonatal O
cardiopulmonary O
bypass O
. O

The O
specific O
interaction O
between O
a O
defined O
structural O
element O
of O
the O
human O
immunodeficiency O
virus O
mRNA O
( O
RRE B
, O
the O
Rev B
response I
element I
) O
and O
the O
virus B
- I
encoded I
protein I
Rev I
has O
been O
implicated O
in O
the O
regulation O
of O
the O
export O
of O
unspliced O
or O
singly O
spliced O
mRNA O
from O
the O
nucleus O
to O
the O
cytoplasm O
. O

Transient O
overexpression O
of O
c B
- I
Jun I
induced O
tenascin B
- I
C I
expression O
in O
primary O
REF O
and O
in O
FR3T3 O
, O
an O
established O
fibroblast O
cell O
line O
. O

Transient O
overexpression O
of O
c B
- I
Jun I
induced O
tenascin B
- I
C I
expression O
in O
primary O
REF O
and O
in O
FR3T3 O
, O
an O
established O
fibroblast O
cell O
line O
. O

2 O
- O
AP O
induced O
marked O
, O
steady O
rises O
in O
mRNA O
accumulation O
from O
both O
transfected O
and O
chromosomally O
integrated O
HIV O
- O
1 O
constructs O
but O
no O
increases O
from O
an O
endogenous O
gene O
encoding O
gamma B
- I
actin I
or O
glucose B
6 I
- I
phosphate I
dehydrogenase I
. O

The O
serum O
levels O
of O
beta B
- I
human I
chorionic I
gonadotropin I
( O
HCG B
) O
and O
placental B
alkaline I
phosphatase I
( O
PLAP B
) O
were O
not O
elevated O
. O

Gel O
filtration O
, O
sedimentation O
velocity O
, O
and O
immunoprecipitation O
experiments O
revealed O
that O
beta4 O
is O
a O
component O
of O
a O
multisubunit O
complex O
( O
AP B
- I
4 I
) O
that O
also O
contains O
the O
sigma4 O
polypeptide O
and O
two O
additional O
adaptor O
subunit O
homologs O
named O
mu4 O
( O
mu O
- O
ARP2 O
) O
and O
epsilon O
. O

The O
2 O
cDNAs O
differed O
in O
the O
length O
of O
their O
respective O
3 O
' O
untranslated O
regions O
, O
of O
577 O
bp O
in O
Cp B
. I
F6 I
and O
72 O
bp O
in O
Cp B
. I
F10 I
, O
in O
both O
of O
which O
a O
putative O
polyadenylation O
signal O
was O
identified O
. O

The O
2 O
cDNAs O
differed O
in O
the O
length O
of O
their O
respective O
3 O
' O
untranslated O
regions O
, O
of O
577 O
bp O
in O
Cp B
. I
F6 I
and O
72 O
bp O
in O
Cp B
. I
F10 I
, O
in O
both O
of O
which O
a O
putative O
polyadenylation O
signal O
was O
identified O
. O

Using O
Southern O
blot O
analysis O
and O
restriction O
mapping O
of O
genomic O
YAC O
( O
yeast O
artificial O
chromosome O
) O
and O
cosmid O
clones O
, O
we O
located O
the O
human B
RIL I
gene I
240 O
- O
260 O
kb O
telomeric O
to O
the O
IRF1 B
gene I
and O
characterized O
its O
genomic O
structure O
. O

The O
binding O
of O
transcription O
factor O
AP B
- I
1 I
and O
vitamin B
D I
receptor I
( O
VDR B
) O
to O
the O
composite O
AP B
- I
1 I
plus I
vitamin I
- I
D I
- I
responsive I
promoter I
region O
( O
AP B
- I
1 I
+ I
VDRE I
) O
of O
the O
human B
osteocalcin I
gene I
was O
characterized O
in O
osteocalcin B
- O
producing O
( O
MG O
- O
63 O
) O
and O
non O
- O
producing O
( O
U2 O
- O
Os O
, O
SaOs O
- O
2 O
) O
human O
osteosarcoma O
cell O
lines O
. O

The O
binding O
of O
transcription O
factor O
AP B
- I
1 I
and O
vitamin B
D I
receptor I
( O
VDR B
) O
to O
the O
composite O
AP B
- I
1 I
plus I
vitamin I
- I
D I
- I
responsive I
promoter I
region O
( O
AP B
- I
1 I
+ I
VDRE I
) O
of O
the O
human B
osteocalcin I
gene I
was O
characterized O
in O
osteocalcin B
- O
producing O
( O
MG O
- O
63 O
) O
and O
non O
- O
producing O
( O
U2 O
- O
Os O
, O
SaOs O
- O
2 O
) O
human O
osteosarcoma O
cell O
lines O
. O

The O
binding O
of O
transcription O
factor O
AP B
- I
1 I
and O
vitamin B
D I
receptor I
( O
VDR B
) O
to O
the O
composite O
AP B
- I
1 I
plus I
vitamin I
- I
D I
- I
responsive I
promoter I
region O
( O
AP B
- I
1 I
+ I
VDRE I
) O
of O
the O
human B
osteocalcin I
gene I
was O
characterized O
in O
osteocalcin B
- O
producing O
( O
MG O
- O
63 O
) O
and O
non O
- O
producing O
( O
U2 O
- O
Os O
, O
SaOs O
- O
2 O
) O
human O
osteosarcoma O
cell O
lines O
. O

The O
binding O
of O
NF B
- I
ATp I
, O
although O
not O
NF B
- I
AT4 I
, O
to O
this O
enhancer O
also O
occurs O
along O
with O
HTLV O
- O
I O
- O
mediated O
infection O
of O
human O
peripheral O
blood O
T O
- O
cells O
. O

The O
binding O
of O
NF B
- I
ATp I
, O
although O
not O
NF B
- I
AT4 I
, O
to O
this O
enhancer O
also O
occurs O
along O
with O
HTLV O
- O
I O
- O
mediated O
infection O
of O
human O
peripheral O
blood O
T O
- O
cells O
. O

Restriction O
enzyme O
mapping O
, O
subcloning O
, O
and O
DNA O
sequencing O
analysis O
of O
recombinant O
phage O
lambda O
and O
P1 O
clones O
revealed O
that O
exons O
encoding O
the O
1 O
. O
9 O
- O
kb O
mouse B
TS I
mRNA I
are O
dispersed O
over O
> O
150 O
kb O
genomic O
DNA O
. O

Mutational O
analyses O
have O
demonstrated O
the O
importance O
of O
sequences O
within O
the O
327 O
bp O
segment O
that O
contain O
a O
putative O
cyclic B
AMP I
responsive I
element I
binding I
protein I
( O
CREB B
) O
binding O
site O
for O
TGF B
- I
beta I
1 I
and O
PMA O
responsiveness O
and O
putative O
PU B
- I
1 I
and O
Sp1 B
binding I
sites I
for O
basal O
promoter O
activity O
. O

Mutational O
analyses O
have O
demonstrated O
the O
importance O
of O
sequences O
within O
the O
327 O
bp O
segment O
that O
contain O
a O
putative O
cyclic B
AMP I
responsive I
element I
binding I
protein I
( O
CREB B
) O
binding O
site O
for O
TGF B
- I
beta I
1 I
and O
PMA O
responsiveness O
and O
putative O
PU B
- I
1 I
and O
Sp1 B
binding I
sites I
for O
basal O
promoter O
activity O
. O

The O
Ng B
/ I
RC3 I
and O
PKC B
- I
gamma I
genes I
have O
a O
similar O
expression O
pattern O
in O
the O
brain O
during O
development O
. O

Along O
with O
previously O
mapped O
genes O
including O
Ly B
- I
1 I
and O
CD20 B
, O
OSBP B
defines O
a O
new O
conserved O
syntenic O
group O
on O
the O
long O
arm O
of O
chromosome O
11 O
in O
the O
human O
and O
the O
proximal O
end O
of O
chromosome O
19 O
in O
the O
mouse O
. O

In O
a O
gntR B
deletion I
mutant I
, O
the O
expression O
of O
a O
chromosomal O
gntT B
: O
: O
lacZ B
fusion O
is O
both O
high O
and O
constitutive O
, O
confirming O
that O
GntR B
is O
the O
negative O
regulator O
of O
gntT B
. O

Significantly O
, O
two O
proximal O
GATA B
- I
1 I
- I
binding I
sites I
( O
- O
118 O
/ O
- O
113 O
and O
- O
98 O
/ O
- O
93 O
) O
and O
a O
region O
located O
within O
- O
518 O
to O
- O
315bp O
of O
the O
mouse B
ALAS2 I
promoter I
were O
essential O
for O
transcriptional O
activation O
during O
chemically O
induced O
differentiation O
of O
MEL O
cells O
, O
implying O
their O
importance O
in O
conferring O
erythroid O
specificity O
to O
the O
ALAS2 B
transcriptional O
activation O
. O

The O
only O
abundant O
viral O
transcript O
expressed O
during O
latency O
is O
the O
latency B
- I
related I
( O
LR B
) O
RNA O
. O

Taken O
together O
, O
these O
results O
demonstrate O
that O
the O
RP B
, O
like O
the O
20S B
proteasome I
, O
is O
functionally O
and O
structurally O
conserved O
among O
eukaryotes O
and O
indicate O
that O
the O
plant B
RPT I
subunits I
, O
like O
their O
yeast O
counterparts O
, O
have O
non O
- O
redundant O
functions O
. O

Immunohistochemical O
staining O
with O
MIB B
- I
1 I
and O
p53 B
antibodies I
showed O
low O
( O
< O
1 O
% O
) O
and O
negative O
reaction O
. O

In O
contrast O
, O
exogenous B
PTHrP1 I
- I
34 I
and I
1 I
- I
86 I
peptides I
did O
not O
significantly O
affect O
IL B
- I
8 I
production O
; O
moreover O
, O
PTHrP B
- I
neutralizing I
antibodies I
did O
not O
inhibit O
the O
production O
of O
IL B
- I
8 I
by O
transfected O
PTHrP B
. O

In O
contrast O
, O
exogenous B
PTHrP1 I
- I
34 I
and I
1 I
- I
86 I
peptides I
did O
not O
significantly O
affect O
IL B
- I
8 I
production O
; O
moreover O
, O
PTHrP B
- I
neutralizing I
antibodies I
did O
not O
inhibit O
the O
production O
of O
IL B
- I
8 I
by O
transfected O
PTHrP B
. O

( O
ii O
) O
An O
AF O
G B
- I
CSF I
level O
> O
2000 O
pg O
/ O
ml O
is O
a O
strong O
positive O
predictor O
of O
CAM O
. O

Six O
of O
the O
gstC B
' I
mutants I
, O
primarily O
in O
the O
C O
- O
terminal O
half O
of O
C B
' I
, O
exhibited O
a O
defect O
in O
the O
ability O
to O
bind O
L B
protein I
. O

MEKs B
and O
ERKs B
inhibited O
IL B
- I
6 I
activation O
of O
Stat3 B
harboring O
a O
mutation O
at O
serine O
- O
727 O
, O
the O
major O
site O
for O
serine O
phosphorylation O
, O
similar O
to O
inhibition O
of O
wild B
- I
type I
Stat3 I
, O
and O
inhibited O
Janus B
kinases I
Jak1 B
and O
Jak2 B
upstream O
of O
Stat3 B
in O
the O
Jak B
- O
STAT B
- O
signaling O
pathway O
. O

An O
amino O
- O
acid O
sequence O
comparison O
revealed O
that O
Bacillus B
YM55 I
- I
1 I
aspartase I
shared O
71 O
% O
homology O
with O
Bacillus B
subtilis I
aspartase I
and O
49 O
% O
with O
Escherichia O
coli O
and O
Pseudomonas B
fluorescens I
aspartases I
. O

An O
amino O
- O
acid O
sequence O
comparison O
revealed O
that O
Bacillus B
YM55 I
- I
1 I
aspartase I
shared O
71 O
% O
homology O
with O
Bacillus B
subtilis I
aspartase I
and O
49 O
% O
with O
Escherichia O
coli O
and O
Pseudomonas B
fluorescens I
aspartases I
. O

A O
736 O
- O
bp O
sequence O
of O
the O
5 O
' O
flanking O
region O
adjacent O
to O
the O
cap O
site O
of O
the O
human B
AFP I
gene I
shows O
a O
61 O
% O
similarity O
with O
the O
corresponding O
region O
of O
the O
mouse B
AFP I
gene I
. O

A O
736 O
- O
bp O
sequence O
of O
the O
5 O
' O
flanking O
region O
adjacent O
to O
the O
cap O
site O
of O
the O
human B
AFP I
gene I
shows O
a O
61 O
% O
similarity O
with O
the O
corresponding O
region O
of O
the O
mouse B
AFP I
gene I
. O

Several O
genes O
or O
transcriptional O
units O
were O
identified O
, O
including O
the O
3 O
' O
end O
of O
ribosomal B
s6 I
kinase I
( O
Rsk3 B
) O
; O
two O
apparently O
intronless O
and O
ORF O
- O
less O
genes O
; O
and O
Gpr31 B
, O
an O
intronless O
, O
putative O
G B
- I
protein I
coupled I
receptor I
. O

Mus81p B
also O
shares O
homology O
with O
motifs O
found O
in O
the O
XPF B
endonuclease I
superfamily I
. O

Agonist O
- O
induced O
receptor O
internalization O
, O
determined O
as O
the O
percent O
of O
total O
[ O
125I O
] O
Tyr0 B
- I
oCRF I
bound O
located O
in O
the O
acid O
- O
resistant O
fraction O
of O
transfected O
Cos O
7 O
cells O
, O
increased O
with O
time O
( O
0 O
- O
60 O
min O
at O
37 O
degrees O
C O
) O
for O
both O
wild O
- O
type O
and O
variant O
oCRF1 B
. O

TGF B
beta I
1 I
expression O
is O
largely O
governed O
by O
three O
AP B
- I
1 I
binding I
sites I
located O
in O
two O
different O
promoters O
of O
this O
gene O
. O

The O
transcription O
factor O
Jun B
( O
c B
- I
Jun I
) O
functions O
as O
a O
recipient O
of O
extracellular O
growth O
signals O
and O
converts O
them O
into O
patterns O
of O
gene O
expression O
. O

Our O
results O
indicate O
that O
the O
minimal O
requirements O
for O
induction O
of O
PEPCK B
by O
PKA B
and O
inhibition O
by O
insulin B
include O
: O
1 O
) O
the O
CREB B
activation I
domain I
, O
2 O
) O
the O
PEPCK B
TATA I
sequence I
, O
and O
3 O
) O
insulin B
- O
responsive O
hepatoma O
cells O
. O

Our O
results O
indicate O
that O
the O
minimal O
requirements O
for O
induction O
of O
PEPCK B
by O
PKA B
and O
inhibition O
by O
insulin B
include O
: O
1 O
) O
the O
CREB B
activation I
domain I
, O
2 O
) O
the O
PEPCK B
TATA I
sequence I
, O
and O
3 O
) O
insulin B
- O
responsive O
hepatoma O
cells O
. O

To O
get O
further O
insights O
into O
the O
molecular O
mechanisms O
that O
control O
tal B
- I
1 I
expression O
, O
we O
have O
isolated O
5 O
' O
sequences O
of O
the O
murine O
gene O
and O
compared O
them O
to O
their O
human O
counterparts O
. O

Although O
the O
Src B
tyrosine I
kinase I
induces O
constitutive O
Stat3 B
phosphorylation O
on O
tyrosine O
, O
activation O
of O
Stat3 B
- O
mediated O
gene O
regulation O
requires O
both O
tyrosine O
and O
serine O
phosphorylation O
of O
Stat3 B
. O

The O
Cdk2 B
- O
cyclin B
- I
D1 I
complex O
did O
not O
phosphorylate O
any O
tested O
substrates O
, O
such O
as O
H1 B
histone I
, O
pRB B
, O
SV40 B
large I
T I
antigen I
, O
p53 B
, O
E2F B
- I
1 I
or O
a O
preparation O
of O
nuclear O
proteins O
from O
HeLa O
cells O
; O
in O
contrast O
, O
Cdk2 B
- O
cyclin B
- I
E I
and O
Cdk2 B
- O
cyclin B
- I
A I
phosphorylated O
these O
proteins O
. O

The O
Cdk2 B
- O
cyclin B
- I
D1 I
complex O
did O
not O
phosphorylate O
any O
tested O
substrates O
, O
such O
as O
H1 B
histone I
, O
pRB B
, O
SV40 B
large I
T I
antigen I
, O
p53 B
, O
E2F B
- I
1 I
or O
a O
preparation O
of O
nuclear O
proteins O
from O
HeLa O
cells O
; O
in O
contrast O
, O
Cdk2 B
- O
cyclin B
- I
E I
and O
Cdk2 B
- O
cyclin B
- I
A I
phosphorylated O
these O
proteins O
. O

The O
Cdk2 B
- O
cyclin B
- I
D1 I
complex O
did O
not O
phosphorylate O
any O
tested O
substrates O
, O
such O
as O
H1 B
histone I
, O
pRB B
, O
SV40 B
large I
T I
antigen I
, O
p53 B
, O
E2F B
- I
1 I
or O
a O
preparation O
of O
nuclear O
proteins O
from O
HeLa O
cells O
; O
in O
contrast O
, O
Cdk2 B
- O
cyclin B
- I
E I
and O
Cdk2 B
- O
cyclin B
- I
A I
phosphorylated O
these O
proteins O
. O

The O
Cdk2 B
- O
cyclin B
- I
D1 I
complex O
did O
not O
phosphorylate O
any O
tested O
substrates O
, O
such O
as O
H1 B
histone I
, O
pRB B
, O
SV40 B
large I
T I
antigen I
, O
p53 B
, O
E2F B
- I
1 I
or O
a O
preparation O
of O
nuclear O
proteins O
from O
HeLa O
cells O
; O
in O
contrast O
, O
Cdk2 B
- O
cyclin B
- I
E I
and O
Cdk2 B
- O
cyclin B
- I
A I
phosphorylated O
these O
proteins O
. O

The O
relatively O
mild O
defects O
observed O
in O
Rpd3 B
mutants I
suggest O
that O
the O
recently O
identified O
Groucho B
and O
dCtBP B
corepressor I
proteins I
do O
not O
function O
solely O
through O
the O
recruitment O
of O
histone B
deacetylases I
. O

The O
immune O
system O
is O
closely O
integrated O
with O
the O
neuroendocrine O
system O
, O
and O
infection O
- O
induced O
increases O
in O
cytokines O
such O
as O
IL B
- I
1 I
, O
IL B
- I
6 I
and O
TNF B
have O
numerous O
effects O
on O
the O
central O
nervous O
system O
. O

The O
immune O
system O
is O
closely O
integrated O
with O
the O
neuroendocrine O
system O
, O
and O
infection O
- O
induced O
increases O
in O
cytokines O
such O
as O
IL B
- I
1 I
, O
IL B
- I
6 I
and O
TNF B
have O
numerous O
effects O
on O
the O
central O
nervous O
system O
. O

P B
- I
CIP1 I
, O
a O
novel O
protein O
that O
interacts O
with O
the O
cytosolic O
domain O
of O
peptidylglycine B
alpha I
- I
amidating I
monooxygenase I
, O
is O
associated O
with O
endosomes O
. O

Null O
mutations O
in O
daf B
- I
3 I
suppress O
mutations O
in O
genes O
encoding O
this O
TGF B
- I
beta I
signal O
, O
its O
receptors O
, O
and O
associated O
Smad B
signal I
transduction I
proteins I
. O

Null O
mutations O
in O
daf B
- I
3 I
suppress O
mutations O
in O
genes O
encoding O
this O
TGF B
- I
beta I
signal O
, O
its O
receptors O
, O
and O
associated O
Smad B
signal I
transduction I
proteins I
. O

daf B
- I
3 I
encodes O
a O
Smad B
protein I
that O
is O
most O
closely O
related O
to O
mammalian B
DPC4 I
, O
and O
is O
expressed O
throughout O
development O
in O
many O
of O
the O
tissues O
that O
are O
remodeled O
during O
dauer O
development O
. O

The O
AtERF B
genes I
were O
differentially O
regulated O
by O
ethylene O
and O
by O
abiotic O
stress O
conditions O
, O
such O
as O
wounding O
, O
cold O
, O
high O
salinity O
, O
or O
drought O
, O
via O
ETHYLENE B
- I
INSENSITIVE2 I
( O
EIN2 B
) O
- O
dependent O
or O
- O
independent O
pathways O
. O

Effect O
of O
heparin O
on O
the O
inactivation O
of O
serum B
lipoprotein I
lipase I
by O
the O
liver O
in O
unanesthetized O
dogs O
. O

It O
is O
present O
in O
the O
nucleus O
of O
the O
cells O
in O
which O
it O
is O
expressed O
and O
can O
phosphorylate O
and O
activate O
the O
cyclic B
AMP I
response I
element I
binding I
proteins I
CREB B
and O
CREM B
tau I
in O
a O
manner O
analogous O
to O
protein B
kinase I
A I
. O

We O
postulate O
that O
CaM B
binding O
by O
HIV B
envelope I
proteins I
is O
likely O
to O
exert O
diverse O
modulatory O
effects O
, O
and O
the O
mechanism O
for O
HIV O
- O
induced O
cytotoxicity O
may O
involve O
, O
in O
part O
, O
inhibition O
of O
CaM B
- O
regulated O
cellular O
functions O
. O

Further O
, O
Ser O
/ O
Thr O
phosphorylation O
of O
downstream O
molecules O
Akt B
and O
p70 B
S6 I
kinase I
was O
inhibited O
. O

We O
conclude O
that O
c B
- I
Myb I
regulates O
the O
RAG B
- I
2 I
promoter I
in O
T O
cells O
by O
binding O
to O
this O
consensus B
c I
- I
Myb I
binding I
site I
. O

The O
malate B
synthase I
gene I
, O
MLS1 B
, O
of O
the O
yeast O
Saccharomyces O
cerevisiae O
is O
transcriptionally O
regulated O
by O
the O
carbon O
source O
in O
the O
growth O
medium O
. O

Ras B
- I
and I
ultra I
- I
violet I
- I
responsive I
protein I
kinases I
that O
phosphorylate O
c B
- I
Jun I
on O
serine O
residues O
at O
positions O
63 O
and O
73 O
and O
stimulate O
its O
transcriptional O
activity O
have O
been O
identified O
. O

Additionally O
, O
MIP B
- I
2A I
antagonizes O
cell O
growth O
regulatory O
role O
of O
MBP B
- I
1 I
. O

Additionally O
, O
MIP B
- I
2A I
antagonizes O
cell O
growth O
regulatory O
role O
of O
MBP B
- I
1 I
. O

Functional O
rearranged O
antibody O
genes O
were O
detected O
with O
JH B
and O
VH B
heavy I
chain I
probes O
and O
with O
Jk B
and O
Vk B
light I
chain I
probes O
. O

Functional O
rearranged O
antibody O
genes O
were O
detected O
with O
JH B
and O
VH B
heavy I
chain I
probes O
and O
with O
Jk B
and O
Vk B
light I
chain I
probes O
. O

Differential O
association O
of O
products O
of O
alternative O
transcripts O
of O
the O
candidate O
tumor B
suppressor I
ING1 I
with O
the O
mSin3 B
/ O
HDAC1 B
transcriptional O
corepressor O
complex O
. O

Expression O
of O
h6 O
. O
1 O
in O
COS O
- O
1 O
cells O
led O
to O
the O
production O
of O
a O
typical O
type B
IV I
PDE I
activity O
in O
that O
cAMP O
, O
but O
not O
cGMP O
, O
served O
as O
substrate O
and O
its O
activity O
was O
insensitive O
to O
either O
Ca2 O
+ O
/ O
CaM B
or O
cGMP O
but O
was O
inhibited O
by O
low O
concentrations O
of O
rolipram O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

In O
vivo O
association O
between O
Shb B
- O
SH3 B
domain O
proteins O
v B
- I
Src I
and O
Eps8 B
was O
detected O
by O
coimmunoprecipitation O
. O

In O
addition O
, O
another O
derivative O
of O
pCMVJS21 O
( O
pCMVJS21DeltaGP O
) O
in O
which O
the O
gag B
, O
pol B
( O
and O
orf B
- I
x I
) O
coding O
sequences O
were O
deleted O
also O
gave O
transformed O
foci O
. O

The O
localization O
of O
ZAP B
- I
70 I
to O
the O
cell O
cortex O
is O
, O
therefore O
, O
regulated O
by O
the O
activity O
of O
SRC B
- I
family I
kinases I
, O
independently O
of O
their O
ability O
to O
phosphorylate O
immunoreceptor O
tyrosine O
- O
based O
activation O
motifs O
of O
the O
TCR B
. O

Interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
is O
a O
potent O
inflammatory O
mediator O
that O
belongs O
to O
the O
family O
of O
C B
- I
X I
- I
C I
chemokines I
. O

Interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
is O
a O
potent O
inflammatory O
mediator O
that O
belongs O
to O
the O
family O
of O
C B
- I
X I
- I
C I
chemokines I
. O

The O
227 O
- O
to O
- O
239 O
region O
blocked O
ADR1 B
activity O
independently O
of O
the O
TAD B
present O
on O
ADR1 B
, O
ADR1 B
DNA O
binding O
, O
and O
specific O
ADH2 B
promoter I
sequences I
. O

The O
unphosphorylated O
form O
of O
RNA B
polymerase I
II I
is O
designated O
IIA O
, O
whereas O
the O
phosphorylated O
form O
is O
designated O
IIO O
. O

Recent O
studies O
using O
isolated O
rat O
adipocytes O
and O
chemically O
synthesized O
PIG O
compounds O
point O
to O
IRS1 B
/ I
3 I
tyrosine O
phosphorylation O
by O
p59Lyn B
kinase I
as O
the O
site O
of O
cross O
- O
talk O
, O
the O
negative O
regulation O
of O
which O
by O
interaction O
with O
caveolin B
is O
apparently O
abrogated O
by O
PIG O
. O

METHODS O
: O
rHb1 B
. I
1 I
or O
human B
serum I
albumin I
was O
administered O
intravenously O
to O
fasting O
male O
volunteers O
. O

METHODS O
: O
rHb1 B
. I
1 I
or O
human B
serum I
albumin I
was O
administered O
intravenously O
to O
fasting O
male O
volunteers O
. O

However O
, O
little O
is O
known O
regarding O
the O
genomic O
organization O
and O
developmental O
expression O
of O
the O
caveolin B
gene I
family I
. O

In O
addition O
, O
a O
noncanonical O
C B
/ I
EBP I
- I
binding I
site I
within O
the O
Gadd45gamma B
promoter I
where O
C B
/ I
EBPbeta I
and O
C B
/ I
EBPdelta I
could O
bind O
, O
was O
identified O
by O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA O
) O
and O
reporter O
gene O
analysis O
. O

In O
addition O
, O
a O
noncanonical O
C B
/ I
EBP I
- I
binding I
site I
within O
the O
Gadd45gamma B
promoter I
where O
C B
/ I
EBPbeta I
and O
C B
/ I
EBPdelta I
could O
bind O
, O
was O
identified O
by O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA O
) O
and O
reporter O
gene O
analysis O
. O

Hematopoietic B
growth I
factors I
are O
being O
used O
to O
accelerate O
the O
recovery O
of O
myelopoiesis O
following O
high O
- O
dose O
chemotherapy O
in O
cancer O
patients O
. O

The O
comparison O
of O
the O
expression O
patterns O
of O
the O
known O
Kv4 B
family I
members I
shows O
subtype O
specificity O
with O
significant O
overlaps O
. O

Two O
mammalian O
enzymes O
, O
the O
haem B
- I
controlled I
repressor I
( O
HCR B
) O
and O
the O
double B
- I
stranded I
RNA I
- I
activated I
inhibitor I
( O
dsI B
) O
, O
phosphorylate O
Ser O
- O
51 O
of O
the O
alpha O
subunit O
, O
thereby O
inhibiting O
the O
exchange O
of O
bound O
nucleotides O
on O
, O
and O
thus O
the O
recycling O
of O
, O
eIF B
- I
2 I
. O

Furthermore O
, O
deletion O
and O
mutation O
analyses O
of O
the O
VCAM B
- I
1 I
promoter I
performed O
with O
chloramphenicol B
acetyltransferase I
constructs I
revealed O
that O
Tax B
was O
trans O
activating O
the O
VCAM B
- I
1 I
promoter I
via O
two O
NF B
- I
kappaB I
sites I
present O
at O
bp O
- O
72 O
and O
- O
57 O
in O
the O
VCAM B
- I
1 I
gene I
promoter I
, O
with O
both O
of O
them O
being O
required O
for O
the O
Tax B
- O
induced O
expression O
of O
this O
adhesion O
molecule O
. O

In O
this O
study O
we O
provide O
evidence O
that O
B B
- I
Myb I
is O
a O
direct O
physiological O
target O
for O
cyclin B
A I
/ O
Cdk2 B
. O

Factors O
influencing O
in O
vitro O
skin B
permeability I
factor I
production O
by O
Vibrio O
cholerae O
. O

Thus O
, O
we O
have O
identified O
an O
activation O
target O
of O
a O
human O
activator O
, O
Oct B
- I
1 I
, O
within O
its O
cognate O
basal O
transcription O
complex O
. O

The O
two O
- O
hybrid O
assay O
was O
then O
performed O
using O
full O
- O
length O
genes O
of O
CI B
, O
HC B
- I
Pro I
, O
P1 B
, O
P3 B
, O
and O
CP B
, O
but O
no O
heterologous O
interactions O
were O
detected O
. O

These O
six O
amino O
acids O
are O
part O
of O
an O
amphipathic O
helix O
that O
is O
highly O
conserved O
among O
nuclear B
hormone I
receptors I
and O
contains O
the O
core O
domain O
of O
the O
ligand O
- O
dependent O
transactivation O
function O
, O
AF O
- O
2 O
. O

axl O
, O
a O
transforming O
gene O
isolated O
from O
primary O
human O
myeloid O
leukemia O
cells O
, O
encodes O
a O
novel O
receptor B
tyrosine I
kinase I
. O

NF B
- I
kappaB I
is O
involved O
in O
the O
regulation O
of O
CD154 B
( O
CD40 B
ligand I
) O
expression O
in O
primary O
human O
T O
cells O
. O

Although O
both O
transfected O
cell O
lines O
contain O
FGF B
- I
1 I
cell I
surface I
receptors I
as O
judged O
by O
crosslinking O
studies O
, O
the O
wild O
- O
type O
transfectants O
are O
refractory O
to O
exogenous O
FGF B
- I
1 I
, O
whereas O
the O
mutant O
transfectants O
respond O
normally O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

NF B
kappa I
B I
was O
activated O
to O
a O
much O
greater O
extent O
by O
roscovitine O
in O
the O
WT O
cells O
than O
in O
Y8 O
cells O
. O

The O
yeast O
gene O
that O
encodes O
eIF B
- I
5 I
, O
designated O
TIF5 B
, O
has O
been O
isolated O
and O
expressed O
in O
Escherichia O
coli O
to O
yield O
a O
catalytically O
active O
eIF B
- I
5 I
protein I
. O

We O
have O
cloned O
and O
sequenced O
the O
mouse B
NMO1 I
cDNA I
, O
which O
encodes O
the O
NAD B
( I
P I
) I
H I
: I
menadione I
oxidoreductase I
[ O
also O
called O
NAD B
( I
P I
) I
H I
: I
( I
quinone I
acceptor I
) I
oxidoreductase I
; O
quinone B
reductase I
; O
azo B
dye I
reductase I
; O
DT B
diaphorase I
; O
EC B
1 I
. I
6 I
. I
99 I
. I
2 I
] O
. O

We O
have O
cloned O
and O
sequenced O
the O
mouse B
NMO1 I
cDNA I
, O
which O
encodes O
the O
NAD B
( I
P I
) I
H I
: I
menadione I
oxidoreductase I
[ O
also O
called O
NAD B
( I
P I
) I
H I
: I
( I
quinone I
acceptor I
) I
oxidoreductase I
; O
quinone B
reductase I
; O
azo B
dye I
reductase I
; O
DT B
diaphorase I
; O
EC B
1 I
. I
6 I
. I
99 I
. I
2 I
] O
. O

As O
expected O
for O
a O
positive O
SpHE B
transcriptional I
regulator I
, O
the O
timing O
of O
SpEts4 B
gene I
expression O
precedes O
the O
transient O
expression O
of O
SpHE B
in O
the O
very O
early O
sea O
urchin O
blastula O
. O

The O
activity O
of O
the O
coat B
protein I
promoter I
of O
chloris O
striate O
mosaic O
virus O
is O
enhanced O
by O
its O
own O
and O
C1 B
- O
C2 B
gene O
products O
. O

The O
sequence O
of O
the O
HIR1 B
gene I
predicts O
an O
88 O
- O
kDa O
protein O
with O
three O
repeats O
of O
a O
motif O
found O
in O
the O
G B
beta I
subunit I
of O
retinal B
transducin I
and O
in O
a O
yeast O
transcriptional O
repressor O
, O
Tup1 B
. O

Conformational O
studies O
combining O
secondary O
structure O
predictions O
, O
CD O
and O
NMR O
spectroscopy O
together O
with O
ELISA O
assays O
, O
showed O
that O
the O
greater O
is O
the O
propensity O
of O
the O
epitope O
for O
helix O
formation O
the O
higher O
is O
the O
recognition O
by O
anti B
- I
K159 I
. O

Prostate B
specific I
antigen I
shows O
the O
metastatic O
cases O
better O
[ O
correction O
of O
worse O
] O
than O
prostatic B
acid I
phosphatase I
. O

Prostate B
specific I
antigen I
shows O
the O
metastatic O
cases O
better O
[ O
correction O
of O
worse O
] O
than O
prostatic B
acid I
phosphatase I
. O

U73 B
contains O
C O
, O
D O
and O
D O
' O
boxes O
and O
a O
12 O
- O
nucleotide O
antisense O
complementarity O
to O
the O
28S B
ribosomal I
RNA I
. O

TSA O
treatment O
, O
however O
, O
did O
not O
detectably O
alter O
enhancer O
factor O
binding O
or O
the O
positioning O
of O
nuc B
- I
1 I
on O
the O
majority O
of O
the O
chromatin O
templates O
indicating O
that O
protein O
acetylation O
and O
chromatin O
remodeling O
may O
be O
limiting O
steps O
that O
occur O
only O
on O
transcriptionally O
competent O
templates O
, O
or O
that O
remodeling O
of O
nuc B
- I
1 I
requires O
additional O
factors O
. O

TSA O
treatment O
, O
however O
, O
did O
not O
detectably O
alter O
enhancer O
factor O
binding O
or O
the O
positioning O
of O
nuc B
- I
1 I
on O
the O
majority O
of O
the O
chromatin O
templates O
indicating O
that O
protein O
acetylation O
and O
chromatin O
remodeling O
may O
be O
limiting O
steps O
that O
occur O
only O
on O
transcriptionally O
competent O
templates O
, O
or O
that O
remodeling O
of O
nuc B
- I
1 I
requires O
additional O
factors O
. O

In O
all O
cases O
, O
high O
- O
level O
expression O
of O
the O
truncated B
avian I
integrins I
was O
obtained O
. O

